Method for detecting proteins with changed energy states or ligand-protein affinity

Through the method of producing small peptides with high concentration enzyme digestion, the sensitivity problems of protein energy state change detection and ligand binding identification in complex protein mixtures are solved, and high sensitivity identification and ligand binding regions are achieved for multiple kinase target proteins. Accurate positioning improves detection accuracy and sensitivity.

CN117665082BActive Publication Date: 2024-11-22DALIAN INSTITUTE OF CHEMICAL PHYSICS CHINESE ACADEMY OF SCIENCES
View PDF 16 Cites 0 Cited by

Patent Information

Application Number
CN202211030145.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2022-08-26
Publication Date
2024-11-22
Estimated Expiration
2042-08-26

AI Technical Summary

Technical Problem

The prior art is difficult to detect protein energy state changes and determine local affinity of ligands and proteins in complex protein mixtures with high sensitivity, especially in case of multi-domain proteins and tiny conformational changes.

Method used

A destructive enzyme cleavage method is adopted, and high concentration protease cleavage produces small peptides less than 5KDa, including two enzyme cleavage sites that reflect the stability of the protein region. It is suitable for bottom-up mass spectrometry analysis, reducing sample complexity and improving detection sensitivity .

Benefits of technology

It significantly improves the sensitivity to protein energy state changes and ligand-bound target protein identification, can identify multiple kinase target proteins in HeLa cell lysate, and can accurately locate ligand-bound regions and determine local affinity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117665082B_ABST
    Figure CN117665082B_ABST
Patent Text Reader

Abstract

The present invention discloses a method for detecting proteins with changed energy states and the affinity between ligands and proteins, and specifically relates to changes in the tolerance to enzyme cleavage after the energy state of proteins changes. A relatively large amount of enzyme is used under non-denaturing conditions to make the protein relatively completely cleaved, directly generating small peptides with a molecular weight of less than 5KDa that can be directly used for bottom-up mass spectrometry analysis. Since the two cleavage sites of this partial peptide are close to each other and can both reflect the stability of the protein region, when the energy state of the protein changes, each site will produce differences. The cumulative effect of the difference in cleavage between the two cleavage sites greatly increases the response amplitude of this partial peptide to the addition of a ligand, so this method has extremely high sensitivity. Using quantitative proteomics to find enzyme-cut differential peptides, analyzing the proteins to which the differential peptides belong and the positions of the proteins, it is possible to determine the proteins and change regions with changed energy states within the entire proteome.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the research field of functional proteome in the direction of proteomics, and specifically relates to detecting proteins with changed energy states in complex protein mixtures such as cell or tissue lysates, or identifying ligand-binding proteins, or measuring the local affinity between ligands and proteins. Background Art

[0002] Proteins are the main bearers of life activities. Traditional quantitative proteomics is mostly used to evaluate the differences in protein abundance in different samples. However, the occurrence of many diseases (such as Parkinson's syndrome and Alzheimer's disease) or the interaction of ligands (including drugs, endogenous metabolites, etc.) with proteins does not change the abundance of specific proteins. It is mainly the folding state of the protein, the post-translational modification of the protein or the function of the protein that has changed (De Souza N, et al, Curr Opin Struct Biol, 2020, 60: 57-65; Cappelletti V, et al, Cell, 2021, 184 (2): 545-559). Changes in protein properties other than abundance will affect the thermodynamic stability of the protein, that is, the energy state. Therefore, the development of methods that can detect changes in protein energy state is of great significance in the diagnosis of diseases, analysis of metabolic molecular pathways, and discovery of drug targets.

[0003] Top-down mass spectrometry can directly analyze intact proteins and monitor changes in the energy state of proteins (Sheng Y et al, International Journal of Mass Spectrometry, 2010, 300 (2011) 118-122), but this method has low throughput and is mainly used for purified proteins, which is difficult to apply in complex protein mixture systems. At present, there are also some non-mass spectrometry methods to detect changes in protein energy states, such as fluorescence resonance energy transfer (Heyduk T, et al, Curr. Opin. Biotechnol, 2002, 13, 292-296), nuclear magnetic resonance (Sakakibara D, et al, Nature, 2009, 458, 102-105), etc. These technologies are suitable for purified proteins and therefore cannot be applied at the proteomics level.

[0004] Bottom-up mass spectrometry is a technique that hydrolyzes large protein fragments into small peptides and then conducts mass spectrometry analysis. This technique can simultaneously identify or quantify thousands or even tens of thousands of proteins. In recent years, a series of methods that combine bottom-up mass spectrometry techniques to analyze changes in protein energy states in high throughput have received widespread attention at home and abroad. This type of method is mainly based on the fact that after the energy state of proteins changes, their tolerance to heat and denaturants changes. Therefore, when the same intensity of heat or denaturant stimulation is applied, proteins with low energy states are more likely to maintain their original conformation and are therefore less likely to precipitate or unfold their structures. By analyzing the difference in the amount of precipitated or unfolded proteins in two or more groups of samples, proteins with changed energy states can be identified. Such technologies include: Cellular Thermal Shift Assay (CETSA, Cellular Thermal Shift Assay, Martinez Molina, et al, Science, 2013, 341(6141): 84-87), Thermal Proteome Profiling (TPP, Thermal Proteome Profiling, Savitski MM, et al, Science, 2014, 346(6205): 55-+), Pulse Proteolysis (PP, Pulse Proteolysis, Chiwook P, et al, Nature methods, 2005, 2(3): 207-212), etc. This type of technology for detecting changes in protein energy states has successfully achieved the identification of drug target proteins (Savitski MM, et al, Science, 2014, 346 (6205): 55-+; Perrin J, et al, Nature Biotechnology, 2020, 38 (3): 303-308), analysis of protein-protein interactions (Tan CS, et al, Science, 2018, 359 (6380): 1170-1177) and analysis of functional post-translational modification groups (Huang JX, et al, Nature methods, 2019, 16, 894-901). However, this type of method analyzes changes in protein energy states at the protein level, so it is impossible to determine the region where the protein energy state changes. In addition, for multi-domain proteins, changes in local protein stability may have only a small effect on the overall stability of the protein, so it may be difficult to capture changes in its stability at the protein level (Mateus A, et al, Proteome Sci, 2016, 15: 13).

[0005] Restriction enzyme digestion (LiP, Limited Proteolysis) was used to study protein conformation a long time ago. This method is based on the different ability of proteins to tolerate enzyme digestion when they are in different conformations. A small amount of non-specific enzyme is used to slightly digest the protein, so that the digestion site mainly occurs in the disordered region, producing larger protein fragments; when the protein conformation changes (for example, the disordered region becomes more ordered), the tolerance of the conformational change part to enzyme digestion changes, and the abundance difference of the large protein fragments produced by immunoblotting is used to determine the region where the protein conformation changes. Since the change of protein energy state is usually accompanied by the change of protein conformation, this method can also be used to study the change of protein energy state and determine the region where the protein energy state changes (Antonio Aceto, et al, The International Journal of Biochemistry & Cell Biology, 1995, 27 (10): 1033-1041; Polverino deLaureto, et al, J Mol Biol, 2003, 334 (1): 129-141). However, since large protein fragments are difficult to directly analyze in a bottom-up analysis mode of mass spectrometry, this technology is limited to the characterization of pure proteins.

[0006] Paola et al. combined restriction enzyme digestion technology with bottom-up mass spectrometry analysis technology (Feng YH, et al, Nature Biotechnology, 2014, 32(10): 1036-+). The large fragment restriction enzyme digestion product (i.e., the above-mentioned large protein fragment) was further denatured with a denaturant, and a second step of complete trypsin digestion was performed, ultimately producing a semi-trypsin-cleaved peptide fragment containing a non-specific enzyme cleavage site and a fully trypsin-cleaved peptide fragment without a non-specific enzyme cleavage site. In the bottom-up analysis mode of mass spectrometry, the difference in abundance of semi- / fully trypsin-cleaved peptide fragments in two or more groups of samples was analyzed by quantitative proteomics to determine the proteins with conformational changes and to determine the regions with conformational changes by analyzing the positions of the peptide fragments on the protein. This method has achieved a large-scale analysis of changes in protein energy states to a certain extent, and captured the interaction between metabolites and proteins in relatively simple biological systems (Piazza I, et al, Cell, 2018, 172 (1-2): 358-372) and changes in protein structure caused by post-translational modification, thermal stimulation and hypotonic pressure (Cappeletti V, et al, Cell, 2021, 184 (2): 545-559). However, the two-step enzyme digestion in this method greatly increases the complexity of the sample and is prone to produce interfering peptides. Therefore, this method is mostly used in relatively simple biological systems. Paola et al. (2020) further developed LiP-Quant (Piazza I, et al, Nature Communication, 2020, 11 (1): 4200). This method requires multiple ligand concentrations based on LiP-MS to increase the credibility of target protein identification. LiP-Quant has achieved the identification of ligand-binding proteins and binding regions in mammalian cell lysates to a certain extent. However, due to the two-step enzyme digestion, semi-trypsin-cleaved peptides containing a non-specific enzyme cleavage site are difficult to identify. In addition, peptides containing a non-specific enzyme cleavage site have a low response to ligand binding. Therefore, its sensitivity for identifying ligand-binding target proteins is very limited. For example, in the identification of the target protein of the broad-spectrum kinase inhibitor staurosporine, if the proportion of kinases in all identified target proteins is required to be above 80%, LiP-Quant can only identify 9 kinase target proteins in HeLa cell lysate (Piazza I, et al, Nature Communication, 2020, 11(1):4200), while the present invention can also identify 111 kinase target proteins in HeLa cell lysate (see Example 3).

[0007] The above-mentioned protein conformation research method based on enzyme cleavage is based on the use of a relatively small amount of enzyme, so that the cleavage site is located in the disordered region, and proteins with different conformations produce different large protein fragments. The difference in the production of large protein fragments is detected by immunoblotting or secondary enzyme cleavage assisted by denaturants to judge the protein with a change in conformation. There is no suggestion to use a large amount of enzyme to cause destructive enzyme cleavage of the protein to directly produce a peptide segment with a molecular weight less than 5KDa and two enzyme cleavage sites that can reflect the stability of the protein region. In the bottom-up analysis mode of mass spectrometry, the difference in the abundance of this part of the peptide segment is analyzed by quantitative proteomics to determine the protein and region with a change in energy state, and the local affinity of ligand-protein binding. In response to the above problems, we have invented a method that can highly sensitively determine the protein and region with a change in energy state in a complex protein mixture system, and measure the local affinity of ligand-protein. This method directly produces a small peptide segment with two cleavage sites that can reflect the stability of the protein region and is suitable for bottom-up mass spectrometry analysis through one-step enzyme cleavage, which greatly reduces the sample complexity, and the differential cumulative effect of the two cleavage sites when the energy state changes greatly increases the change amplitude of the detected peptide segment, so this method has extremely high sensitivity in detecting changes in the energy state of the protein. For example, compared with LiP-Quant, when the proportion of kinases in all identified staurosporine target proteins is greater than 80%, this method can identify 111 kinases in HeLa cell lysate, which is 12.3 times higher than LiP-Quant (9 kinases) (Example 3). This method outputs quantitative results in units of peptide segments, and can also be used to calculate the affinity of local protein regions to ligand binding when multiple ligand doses are used. Summary of the invention

[0008] The purpose of the present invention is to develop a method that can detect proteins and protein regions with changed energy states or measure the local affinity of ligand-protein binding in complex systems with high sensitivity, namely, a peptide-centric protein local stability assay (PELSA), hereinafter referred to as PELSA.

[0009] The principle is that after the energy state of the protein changes, the regional or global stability of the protein changes, so its ability to resist external damage changes. The present invention utilizes that enzymatic cleavage is a destructive process, and the degree of resistance to the damage caused by enzymatic cleavage changes after the energy state of the protein changes. Under high protease concentrations, the protein is first cut into larger subunits. Since enzymatic cleavage is a destructive process, the structure of the subunit in a high energy state or without ligand binding is rapidly unfolded, inducing further enzymatic cleavage, and finally producing a small peptide segment (<5 KDa) with two enzymatic cleavage sites that can reflect the stability of the protein region, which is suitable for bottom-up mass spectrometry analysis. However, the protein region in a low energy state or with ligand binding still maintains a stable structure, and it is difficult to enter the active pocket of the protease, so it is not easy to produce small peptide segments in this region. Proteins with different energy states are determined by comparing the abundance differences of such peptide segments; analyzing the position of the differential peptide segments on the protein can determine the protein region with different energy states. In this method, the protein directly produces a small peptide containing two cleavage sites that can reflect the stability of the protein region under non-denaturing conditions. Since the two cleavage sites of the small peptide are close to each other, when the energy state changes or a ligand binds, each site will produce a difference. The accumulation of differences between the two sites makes the peptide segment respond more significantly to changes in the protein energy state or ligand binding. In addition, since this method performs a more thorough destructive cleavage of the protein, the cleavage sites are not limited to the disordered region, so more peptides reflecting changes in protein stability can be produced. Furthermore, this process only uses one protease, and the complexity of the cleavage peptide segment is greatly reduced, so it can cover more proteins. The above characteristics make this method highly sensitive.

[0010] When a ligand is added to a complex protein sample, the binding of the ligand to its target protein will cause the energy state of the ligand binding region of the target protein to change. This method can be used to analyze the energy state of the entire proteome to determine the ligand binding protein and the ligand binding region.

[0011] The principle of this technology for determining the local affinity of ligand-protein binding is that when the saturation concentration is not reached, the regional stability of the target protein changes in a dose-dependent manner with the concentration of the added ligand. By detecting the abundance of small peptide fragments cleaved from samples treated with different ligand concentrations, the local affinity of the ligand-protein region can be calculated;

[0012] The small peptide detected by this technology has two cleavage sites that reflect the stability of the protein region; the cleavage site means that the protein has different stabilities in different regions under its tested conformation, and therefore has different degrees of difficulty in cleavage. The cleavage site generated in this case is called the cleavage site that reflects the stability of the protein region.

[0013] The present invention adopts the following technical solution:

[0014] (a) Perform destructive enzymatic cleavage on protein solutions in different energy states or protein solutions incubated with ligands of different concentrations according to a certain ratio of enzyme to protein, so that most proteins can produce small peptides with a molecular weight less than 5KDa containing two enzymatic cleavage sites that can reflect the stability of the protein region;

[0015] (b) Quantitative analysis of small peptide fragments cleaved by enzymes in the bottom-up analysis mode of mass spectrometry;

[0016] (c) Analyze the differences in the abundance of small peptide fragments cut by enzymes to determine the proteins and protein regions whose energy states have changed and the local affinity of ligand-protein binding.

[0017] The specific steps include:

[0018] 1) The protein solution in step (a) must maintain the conformation of the protein to be tested. If the tissue or cell lysate is obtained by lysis, the tissue or cells should be lysed in a gentle manner, including one or more of the liquid nitrogen repeated freeze-thaw method, liquid nitrogen grinding method, and homogenization method. The lysate used should also be able to maintain the conformation of the protein to be tested.

[0019] 2) When studying the binding protein of the ligand, the biological samples containing the protein are divided into two groups, one of which is added with a certain concentration of ligand molecules as the experimental group, and the other is added with a blank solvent as the control group; but it is not limited to two groups, and the ligand group can also be multiple groups of samples containing different concentrations of ligands.

[0020] 3) Add enzyme according to the mass ratio of enzyme to protein of 1:1-1:50, and perform enzymolysis at a certain temperature for 0.5min-60min. The enzyme cutting is performed on an oscillator at a speed of 1000rpm-1500rpm.

[0021] 4) The sample digested in step 3) was heated in a metal bath at 100° C. for 5 min to terminate the enzymatic hydrolysis.

[0022] 5) After step 4), a precipitate is produced in the heated sample, which is dissolved with 6 M guanidine hydrochloride, and tris(2-carboxyethyl)phosphine (TCEP) with a final concentration of 10 mM and chloroacetamide (CAA) with a final concentration of 40 mM are added and heated at 95° C. for 5 min to alkylate the sample after enzyme cleavage.

[0023] 6) Step 5) The alkylated sample was transferred to a 10KDa ultrafiltration tube and centrifuged at 14000g for 20min-1h to collect the peptides obtained by centrifugation. The ultrafiltration membrane was then washed with 200μL pH 8.2 buffer and the peptides obtained by ultrafiltration were combined.

[0024] 7) The peptides generated in step 6) are quantified by mass spectrometry, and the quantification methods include labeled quantification and label-free quantification.

[0025] 8) Analyze the quantitative results of proteins at the peptide level, and use the difference significance or difference fold of the first, second, third or fourth largest peptide segment as the difference significance or difference fold of the protein to screen reliable differential proteins.

[0026] 9) The peptides with differences are assigned to the corresponding protein sequences or structures to determine the protein regions where the energy state changes; the change multiples of the peptides under different ligand concentrations and the corresponding ligand concentrations are fitted to a four-parameter logarithmic equation Y = Bottom + (Top-Bottom) / (1 + 10^(LogEC 50 -X)*Hill Slope)) to calculate the local affinity between the ligand and the protein, which is the EC in the equation 50 .

[0027] Compared with the existing methods, the innovation and advantages of the present invention are embodied in the following aspects:

[0028] 1) The present invention, namely PELSA, utilizes enzyme cleavage, which is a destructive process. A relatively large amount of enzyme is used, so that under non-denaturing conditions, the destructive effect of enzyme cleavage is utilized to enable most proteins to produce small peptides with a molecular weight of less than 5KDa, and these peptides are identified and quantified by mass spectrometry. The small peptides identified by PELSA contain two enzyme cleavage sites that can reflect the stability of the protein region and can be directly subjected to bottom-up mass spectrometry analysis. If the energy state of the protein changes or binds to a ligand, the cumulative effect of the difference between the two enzyme cleavage sites makes the peptides have a larger response. And this method uses a relatively large amount of enzyme, so it can produce more peptides that respond to ligand binding. For example, in Example 2, the number of peptides identified by PELSA that respond to the ligand is 2-5 times that of the comparative method LiP-MS; and the response amplitude of these peptides measured in PELSA is 4-6 times that in LiP-MS.

[0029] 2) Wide application range. Compared with the traditional affinity chromatography-based method, the method of the present invention does not require chemical modification of the ligand molecule when determining the ligand-binding protein, and can theoretically be used for any ligand. In addition, the identification of the ligand-bound target protein does not depend on the strength of the binding between the two, so it can be applied to the identification of low-affinity ligand molecules bound to the target protein. For example, in Examples 4-6, the identification of the metabolic molecules folic acid, leucine and diketoglutarate (αKG) target proteins was successfully achieved. Among them, the identification of the αKG target protein in Example 6 represents the largest number of known αKG target proteins identified in only one experiment.

[0030] 3) It is possible to determine the protein regions with different energy states or the binding regions of the ligands. Compared with the currently widely used TPP (Thermal Proteome Profiling) method, this method can determine the regions with changed energy states or the binding regions of the ligands by analyzing the positions of the changed peptides in the proteins. As shown in Example 3, this method has achieved the identification of the action regions of the kinase inhibitor staurosporine on 150 kinases.

[0031] 4) High sensitivity. When capturing the differences in protein energy state or ligand binding-induced enzymatic cleavage at the protein level, local differences are averaged over the entire protein; this method captures the local differences in protein energy state or ligand binding-induced differences directly at the peptide level, so this method is more capable of capturing subtle differences. In addition, this method does not rely on the identification of peptides with special properties to determine the ligand action area (for example, peptides containing non-specific enzymatic cleavage sites must be identified in LiP-MS), so it is easier to identify peptides with differences. For example, in Example 3, the number of kinase target proteins of the broad-spectrum kinase inhibitor staurosorporine identified by PELSA was 2.1 times that of TPP and 12.3 times that of LiP-Quant.

[0032] 5) Evaluate the local affinity of ligand-protein binding. Divide the protein samples into multiple groups and add different concentrations of ligands to each group. When the saturation concentration is not reached, the tolerance of the target protein to enzyme cleavage changes with the change of the ligand concentration. The affinity information can be obtained by fitting a four-parameter logarithmic equation with the change multiple of the abundance of the peptide fragments cleaved by the enzyme as the ordinate and the concentration of the ligand as the abscissa. Multiple peptide fragments may be identified for a protein, and the affinity curve of each peptide fragment reflects the local binding affinity of the ligand to the region. For example, in Example 11, the local affinity between the ligand and the protein measured by PELSA is very close to the affinity measured by thermophoresis.

[0033] 6) It has broad application prospects. Protein binding to ligands, protein post-translational modification, changes in protein structure, and protein-protein interactions can all lead to changes in the energy state of proteins. Therefore, this method can be applied to systems where various external disturbances lead to changes in the energy state of proteins, providing a powerful tool for solving a variety of biological problems. Example 7 demonstrates the use of PELSA to analyze changes in the energy state of proteins due to protein-protein interactions; Example 8 demonstrates the use of PELSA to analyze changes in the energy state of proteins due to interactions between peptides containing post-translational modifications and proteins; Example 9 demonstrates the use of PELSA to analyze changes in the energy state of proteins due to interactions between metal ions and proteins. BRIEF DESCRIPTION OF THE DRAWINGS

[0034] Figure 1 PELSA implementation flow chart: Proteins with different energy states (a protein in a ligand-bound state and a protein in a non-ligand-bound state as shown in the figure) are subjected to destructive enzymatic cleavage according to a certain ratio of enzyme to protein. The ligand group has a more stable binding region due to the binding of the ligand to the protein, so the structure is less likely to stretch, resulting in less cleavage than the blank group. After enzymatic cleavage, the enzymatic cleavage products are denatured and alkylated, and the peptides cleaved by the enzyme are separated by ultrafiltration for quantitative mass spectrometry analysis.

[0035] Figure 2 PELSA was applied to analyze proteins whose energy status changed after cell lysate was treated with the anti-breast cancer drug lapatinib. (A) Protein hierarchy volcano plot corresponding to 100nM lapatinib: Quantitative values ​​of peptides obtained by treating BT474 cell lysate with 100nM lapatinib or DMSO (4 replicates), using Empirical Bayes t-test to calculate the fold change (FC) and P value of each peptide. The peptide with the smallest P value in each protein represented the protein, and the log2FC and -log 10 Pvalue is plotted as a scatter plot. (B) ERBB2 two-dimensional stability change diagram: log2FC of ERBB2 peptides quantified and their corresponding positions on the ERBB2 two-dimensional sequence. (C) ERBB2 local affinity diagram: log2FC of ERBB2 peptides at different lapatinib concentrations. (D) Volcano diagram on the protein level corresponding to 1μM lapatinib. (E) Two-dimensional stability change diagram of off-target kinases of lapatinib identified using kinases CHEK2, SLK, RIPK2, and YES1 as examples. (F) Western blotting results prove that PTGES2 is stabilized after the addition of lapatinib.

[0036] Unless otherwise specified, fold change, FC (abbreviation of fold change) or ratio in this specification refers to the ratio of peptide abundance between the experimental group and the control group.

[0037] Figure 3Comparison of PELSA and LiP-MS in the identification of proteins with energy state changes after treatment of HeLa cell lysate with methotrexate (MTX) and SHP099. (A) (Upper left) / (Upper right) Volcano plot at the peptide level obtained by LiP-MS / PELSA for HeLa cell lysate treated with 10μM MTX. (Lower left) / (Lower right) Volcano plot at the peptide level obtained by LiP-MS / PELSA for HeLa cell lysate treated with 10μM SHP099. (B) In the MTX and SHP099 treatment systems, the number of target protein peptides identified by PELSA that are responsive to the ligand is 2 and 5.25 times that of LiP-MS, respectively. (C) The change folds of the target protein DHFR and PTPN11 peptides identified by PELSA that are responsive to the ligand are 4.3 and 6.4 times that of LiP-MS, respectively.

[0038] Figure 4PELSA has extremely high sensitivity in identifying proteins with changes in energy state (using the screening of target proteins of the broad-spectrum kinase inhibitor staurosporine as an example). (A) Volcano plot of protein levels corresponding to K562 cell lysate (left) and HeLa cell lysate (right) treated with 20μM staurosporine. (B) Comparison of the number of staurosporine target proteins identified by PELSA in K562 cell lysate, PELSA in HeLa cell lysate, published LiP-Quant in HeLa cell lysate, and published TPP in K562 cell lysate (hereinafter referred to as PELSA (K562), PELSA (HeLa), LiP-Quant (HeLa), and TPP (K562)), where the horizontal axis represents the total number of target proteins identified and the vertical axis represents the number of kinases among the identified target proteins. (C) The number of proteins, peptides and kinases identified by LiP-Quant(HeLa), TPP(K562), PELSA(K562) and PELSA(HeLa). (D) Comparison of protein sequence coverage of all proteins identified by PELSA(HeLa) and LiP-Quant(HeLa) (left); Comparison of protein sequence coverage of kinases screened by PELSA(HeLa) and LiP-Quant(HeLa) (right). This figure indicates that PELSA can identify target proteins even when the protein sequence coverage is low. (E) The segmented violin plot shows the distribution of thermal melting points of kinases screened by PELSA(HeLa), PELSA(K562) and TPP(K562) and all quantified kinases. This figure shows that PELSA also has a good identification effect on thermostable and thermosensitive target proteins. (F) Overlap of all staurosporine target proteins identified by PELSA(K562) and PELSA (HeLa). (G) Density distribution of the stability change significance of peptides located in the kinase domain and other peptides identified by (left) PELSA (K562) and (right) PELSA (HeLa) (the horizontal axis represents the significance of the change, i.e. -log 10 Pvalue, which is calculated by Empirical Bayes t-test, and the ordinate represents the density size). The donut chart shows the proportion of peptides located in the kinase domain, very close to the kinase domain (±10 amino acid residues from the kinase domain), the protein to which the peptide belongs has no kinase domain, and the proportion of peptides located outside the kinase domain among the significantly changed peptides. It can be seen that most of the peptides located in the significantly changed are from the kinase domain.

[0039] Figure 5 PELSA was used to analyze proteins whose energy status changed after metabolites were treated in HeLa cell lysates. (A) Volcano plot of protein hierarchy corresponding to K562 cell lysates treated with 50μM folic acid (folate). (B) PELSA plot of 3D stability change of DHFR after folate binding, with the protein region with the largest stability change indicated by arrows. (C) PELSA plot of 3D stability change of ATIC after 50μM folate was added, with arrows indicating the protein fragment with the largest stability change. (D) PELSA plot of 2D stability change of MTHFR after 50μM folate was added. (E) PELSA plot of 3D stability change of GART after 50μM folate was added, with arrows indicating the protein fragment with the largest stability change. (F) PELSA plot of 2D stability change of P3H1 after 50μM folate was added. (G) Volcano plot of protein hierarchy corresponding to K562 cell lysates treated with 5mM leucine (leucine). (H) Two-dimensional stability change diagram of LARS1 measured by PELSA after adding 5mM leucine. (I) Topological structure diagram of membrane protein SLC1A5, 190-212, 493-502 and 523-541 are the starting and ending positions of the three quantified peptides, and their corresponding |log2FC| are also marked next to the corresponding peptides. (J) Two-dimensional stability change diagram of PPIP5K1 and PPIP5K2 measured by PELSA after adding 5mM leucine. (K) Protein hierarchy volcano diagram corresponding to HeLa cell lysate treated with 2mM dioxoglutarate (αKG), the dotted lines represent -log 10 Pvalue = 3.4 and log2FC = -0.5. Satisfies -log 10 Among the 40 proteins with Pvalue>3.4 and log2FC<-0.5, 30 are known αKG-affected proteins. (L) Two-dimensional stability change diagram of EGLN1, RSBN1L and KDM3B measured by PELSA after HeLa cell lysate was treated with 2mM αKG; the energy change regions measured by PELSA are all known αKG-affected regions.

[0040] Figure 6PELSA analyzes changes in the local energy state of proteins due to protein-protein interactions in HeLa cell lysates (using antibody and antigen binding as an example). (A) Schematic diagram of PELSA identifying antibody binding epitopes in cell lysates. (B) (Left) Volcano plot of the protein hierarchy corresponding to HeLa cell lysates treated with DHFR antibodies, (Right) Volcano plot of the protein hierarchy corresponding to HeLa cell lysates treated with CDK9 antibodies. (C) Three-dimensional stability change map of DHFR measured by PELSA after DHFR antibody treatment (PDB:1BOZ), the spherical shaded part indicates the antibody binding epitope, and the arrow indicates the protein fragment with the largest change in stability. (D) (Top) Two-dimensional stability change map of DHFR measured by PELSA after DHFR antibody treatment, (Bottom) Two-dimensional stability change map of CDK9 measured by PELSA after CDK9 antibody treatment. (E) Changes in the abundance values ​​of two peptides NPATTNQTEFERVF and NPATTNQTEFER of CDK9 after CDK9 antibody treatment.

[0041] Figure 7 PELSA was used in BT474 cell lysate to analyze the changes in the local energy state of proteins due to the interaction between post-translational modifications and proteins (taking the identification of tyrosine phosphorylation recognition domains as an example). (A) Schematic diagram of PELSA identifying post-translational modification recognition domains in cell lysate. (B) PELSA was used to calculate the -log of each peptide using pSEEI and YEEI as control groups. 10 Pvalue (pYEEI / pSEEI) and -log 10 Pvalue (pYEEI / YEEI), expressed as -log 10 Pvalue (pYEEI / pSEEI) and -log 10 The peptide with the largest sum of Pvalue (pYEEI / YEEI) represents the protein, and a scatter plot is made at the protein level. (C) The -log 10 Pvalue (pYEEI / pSEEI) and -log 10Pvalue (pYEEI / YEEI), scatter plot at the protein level. (D) Violin plot showing the distribution of log2FC of peptides located in the SH2 domain and peptides outside the SH2 domain for the 9 proteins containing SH2 domains screened by PELSA. (E) Two-dimensional stability change diagram of proteins containing SH2 domains screened by PELSA, taking YESI, TNS3, PLCG1 and GRB10 as examples. (F) Two-dimensional stability change diagram of calcium ion binding proteins screened by PELSA, taking EFHD1 and CALM1 as examples.

[0042] Figure 8 PELSA is used to analyze proteins whose energy states change after HeLa cell lysate is treated with metal ions (using zinc ions as an example). (A) Protein hierarchy volcano plot corresponding to HeLa cell lysate treated with 30μM zinc ions. (B) (Left) The proportion of metal ion binding proteins among all identified proteins, (Right) The proportion of metal ion binding proteins among the 280 proteins that are significantly stabilized, and the pie chart on the right shows the proportion of zinc ion binding proteins among the stable metal ion binding proteins. (C) The bar chart shows the number of various metal ion binding proteins among the significantly stabilized metal ion binding proteins. (D) The distribution of log2FC of peptides outside the zinc finger structure and peptides inside the zinc finger structure for the 60 proteins containing zinc finger structures screened by PELSA. (E) Two-dimensional stability change diagram of proteins containing zinc finger structures screened by PELSA: using SQSTM1, TRAD1, CHAMP1 and YY1 as examples. (F) Two-dimensional stability change diagram of LIMA1, a zinc ion binding protein without zinc finger structure, after adding 30μM ZnCl2, in which the three peptides located in the LIM domain are labeled as 1, 2, and 3. (G) Partial three-dimensional structure diagram of LIMA1 (LIM domain), the ball represents zinc ion, and the labeling order of the three identified LIM domain peptides is the same as (F). (H) The distribution of log2FC of peptides located outside the EF-hand / EH motif and peptides located inside the EF-hand / EH motif for 20 proteins containing EF-hand / EH motif screened by PELSA. (I) 9 proteins containing Fe 2+ -binding domain protein, located in Fe 2+ -binding domain and the peptide located outside the Fe 2+ -binding domain. (J) A localized volcano plot of the protein hierarchy corresponding to the HeLa cell lysate treated with 30 μM ZnCl2, retaining only proteins with increased energy status after the addition of ZnCl2 (-log 10Pvalue>6,log2FC>0). (K) Two-dimensional stability change diagram of IQ-motif-containing proteins UBE3C, MYO1B, MYO1C and B30.2SPRY domain-containing HNRNPU after adding 30μM ZnCl2. (L) Log2FC distribution of peptides outside the P-loop-NTPase domain and peptides located in the P-loop-NTPase domain of PSMC1-6 proteins after adding 30μM ZnCl2.

[0043] Fig. 9 Comparison of proteome coverage and identification of proteins with altered energy states by PELSA based on different enzymes. (A) Comparison of the number of peptide identifications by trypsin-based PELSA, chymotrypsin-based PELSA, and proteinase K-based PELSA (hereinafter referred to as Trypsin-PELSA, Chymotrypsin-PELSA, and Proteinase K-PELSA, respectively). (B) Venn diagram showing the overlap of proteins identified by Trypsin-PELSA, Chymotrypsin-PELSA, and Proteinase K-PELSA. (C) Volcano plots of the protein hierarchy obtained by Trypsin-PELSA (left), Chymotrypsin-PELSA (middle), and Proteinase K-PELSA (right) of HeLa cell lysate treated with 20 μM methotrexate (MTX).

[0044] Fig.10PELSA combined with dimethyl labeling quantitative method to identify proteins whose energy status changes after HeLa cell lysate treatment with three heat shock protein inhibitors. (A) Structural diagrams of three heat shock protein inhibitors, geldanamycin (left), tanespimycin (middle), and ganetespib (right). (B) The experimental groups were added with 100μM geldanamycin, 100μM tanespimycin, and 100μM ganetespib, respectively, and the control group was an equal volume of blank solvent. The second most changed peptide was used to represent the protein to which it belongs, and the two log2FCs obtained by two mass spectrometry repetitions were scatter plots of the horizontal and vertical axes, respectively. (C) After the addition of geldanamycin, the change in the abundance of peptides in different domains of HSP90AA1, HSP90AB1, HSP90B1, and HSP90AB2P. The horizontal axis represents the sequence of the protein, and the vertical axis represents the log2FC. (D) Thermal shift assay was used to verify the interactions between MAT2A and ganetespib, AKR1C2 and ganetespib, and AKR1C2 and geldanamycin.

[0045] Fig.11 PELSA evaluates the local affinity between ligands and proteins. (A) The change fold of the abundance of heat shock protein HSP90AA1, HSP90AB1, HSP90B1 and TRAP1 peptides at different ganetespib concentrations. (B) The affinity between the heat shock protein family proteins and three inhibitors calculated by PELSA. The horizontal axis represents different inhibitor concentrations, and the inhibitor concentration increases from left to right. The vertical axis represents the change fold of the abundance of the peptides before and after the addition of the drug. A change fold of 1 indicates no change. The marked values ​​represent the half-maximal inhibitory concentration of the three inhibitors for HSP90AA1 calculated by PELSA. (C) Represents the affinity between the three heat shock protein inhibitors and purified HSP90AA1 characterized by micro-scale thermophoresis (MST). The marked values ​​in the figure are the dissociation constants between HSP90AA1 and the three heat shock protein inhibitors measured by MST.

[0046] Fig.12 The responses of peptides containing two cleavage sites reflecting protein stability and peptides containing one cleavage site reflecting protein stability to changes in protein energy status were compared. Fig.12 (Top) / (Bottom) respectively represent the log2 change fold of the abundance of peptides containing two / one enzyme cleavage sites reflecting protein region stability after adding 100 μM geldanamycin, and the horizontal / vertical axes respectively represent the log2 change fold of the abundance of peptides measured by the first / second mass spectrometry repetitions. DETAILED DESCRIPTION

[0047] In order to more clearly explain the technical solution of the present invention and reflect the advantages of the invention, the present invention is further described in detail below in conjunction with embodiments, but the invention is not limited to the scope of the embodiments.

[0048] In the following examples: Example 1 and Examples 4-9 illustrate that this method can be used to analyze anticancer drugs, metabolites, antibodies, peptides containing post-translational modifications, and proteins and protein regions whose energy states change after metal ion treatment of cell lysates; Example 2 proves that PELSA can produce more peptides that respond to changes in energy states or binding to ligands, and the amplitude of changes in these peptides in PELSA is much greater than the amplitude of changes identified in the comparative method LiP-MS. Example 3 proves that PELSA is currently the most sensitive method for identifying proteins and protein regions whose energy states change. Example 10 illustrates that the use of other non-specific or specific enzyme cleavages can also be used to identify proteins whose energy states change by detecting peptides containing two cleavage sites that reflect the stability of the protein region. Example 11 illustrates that the quantification of peptides by PELSA can also use a quantitative method based on dimethyl labeling. Example 12 illustrates that the method can be used to determine the affinity of a ligand and its binding region; Example 13 demonstrates that a peptide containing two cleavage sites that can reflect the stability of a protein region is more sensitive to changes in the energy state of the protein; in addition, Examples 1-9 also illustrate that the method can be used to identify drugs, broad-spectrum kinase inhibitors, metabolites, antibodies, peptides containing post-translational modifications, and binding proteins and binding regions of metal ions; in Examples 1-9, the binding of the ligand to the target protein will lead to changes in the conformation of the binding protein, thus illustrating that the method is also applicable to the study of protein conformational changes.

[0049] In Example 1, after 100 nM lapatinib was used to treat BT474 cell lysate, only the energy state of ERBB2, a known target protein of lapatinib, changed significantly (-log 10Pvalue>5), and the region where its energy state changes is exactly the region of action of lapatinib, namely the kinase domain, proving that PELSA can be used to identify proteins and regions where energy state changes, ligand-binding proteins and binding regions. According to the results of PELSA, we also found that when the concentration of lapatinib increases to 1 μM, more kinase off-target proteins will appear; Example 2 compares the identification of energy state-changing proteins after MTX and SHP099 treatment of HeLa cell lysate by LiP-MS and PELSA to prove that PELSA can identify more peptides that respond to protein energy state changes or ligand binding (2-5 times that identified by LiP-MS), and in addition, the response of some peptides to binding ligands or energy state changes is 4-6 times that of LiP-MS. In Example 3, PELSA identified 121 and 111 staurosoprine kinase target proteins in K562 and HeLa cell lysates, respectively, which are 2.1 times the number of kinase target proteins identified by the TPP method reported in the literature (53) and 12.3 times the number of kinase target proteins identified by the LiP-Quant method reported in the literature (9) when the same kinase target protein ratio was achieved. This result shows that the invention is currently the most sensitive method for identifying proteins with changed energy states. Examples 4-6 show that PELSA can highly sensitively identify weak ligand-protein interactions and locate ligand action areas; in Example 7, PELSA successfully identified the antigenic epitope of the antibody in HeLa lysate, suggesting that PELSA can be used to identify other protein-protein interaction interfaces; in Example 8, PELSA successfully identified the recognition domain of tyrosine phosphorylation (pYEEI) in BT474 cell lysate, providing a powerful tool for finding recognition domains of other post-translational modifications. In Example 9, after the addition of zinc ions, PELSA successfully identified 112 zinc ion binding proteins in the cell lysate and accurately located the zinc ion binding area, indicating that PELSA's identification of ligand-protein interactions is independent of the size of the ligand. In addition, according to the PELSA results, the addition of zinc ions stabilized the calcium ion binding motif, EF-hand / EH motif, while the IQ motif bound to the EF-hand motif was destabilized, which may be due to the binding of zinc ions to the EF-hand motif, causing it to dissociate from the IQ motif, thereby causing the IQ motif to destabilize. This result also suggests that PELSA can be used to study the binding interface of the complex.Example 10 explored whether other enzymes can be used to replace trypsin in PELSA. The results showed that although the number of peptides and proteins identified using chymotrypsin and proteinase K was much less than that of trypsin, the identification of MTX target proteins could be achieved, suggesting that the identification of high-abundance target proteins is not limited to the use of trypsin. Example 11 explored whether PELSA can be combined with a quantitative method of dimethyl labeling to achieve the identification of heat shock protein inhibitor target proteins. The results showed that the screening strategy of the second largest peptide segment combined with the dimethyl labeling quantitative method can highly specifically identify the target protein and off-target protein of heat shock protein inhibitors. Example 12 proves that PELSA can accurately measure the binding affinity of ligands and proteins. Example 13 proves that peptides containing two enzyme cleavage sites that can reflect the stability of the protein region are more sensitive to changes in the energy state of the protein.

[0050] Example 1 PELSA was used to analyze proteins and protein regions whose energy status changed after BT474 cell lysate was treated with the anticancer drug lapatinib.

[0051] (1) Take a large dish of BT474 cell sample (cell count is about 5*e7), resuspend it in 1mL PBS buffer containing 1% (volume ratio) protease inhibitor (Sigma, catalog number P8340-5mL). Repeatedly freeze and thaw in liquid nitrogen three times (freeze in liquid nitrogen for two minutes, thaw in a 37°C water bath for two minutes, and cycle three times) to obtain a mixture of cell fragments and cell lysate. Centrifuge at 500g, 4°C for 10 minutes, take the supernatant to obtain cell lysate, and use Pierce TM The protein concentration was determined by 660 nm Protein Assay (Thermo, USA).

[0052] (2) The protein concentration of the extracted cell lysate was adjusted to 1 mg / mL using cell lysis buffer (PBS buffer containing 1% (volume ratio) protease inhibitor (Sigma, Catalog No. P8340-5mL)). Four portions of cell lysate were taken into EP tubes, 50 μL each, and 0.5 μL of lapatinib (Selleck, Catalog No. S2111) of different stock solution concentrations were added to make the final concentrations of 100 nM, 1 μM, 10 μM, 100 μM (lapatinib stock solution concentrations corresponded to 10 μM, 100 μM, 1 mM, 10 mM; lapatinib was dissolved in DMSO) as the experimental group. Another 50 μL cell lysate was added with 0.5 μL DMSO as the control group. The experimental group and the control group were repeated four times and incubated at room temperature for 30 min.

[0053] (3) Trypsin (Sigma, Catalog No. T1426) was added to the experimental group and the control group at a ratio of 1:2 (mass ratio) of enzyme to protein. The enzyme was digested on an oscillator at 37°C and 1000 rpm for 1 min. 165 μL of 8 M guanidine hydrochloride (Sigma, Catalog No. G3272) pH 8.2 hydroxyethylpiperazine ethanesulfonic acid (HEPES, purchased from Sigma, Catalog No. H3375) buffer was added to terminate the enzymatic hydrolysis to obtain the enzymatic solution.

[0054] (4) TCEP (Sigma, Catalog No. C4706) with a final concentration of 10 mM and CAA (Sigma, Catalog No. 22790) with a final concentration of 40 mM were added to the above enzymatic hydrolyzate, respectively, and heated at 95°C for 5 min. After cooling to room temperature, the sample was further transferred to a 10 KDa ultrafiltration tube (Sartorius, Catalog No. VN01H02), centrifuged at 14000 g for 50 min, and the enzymatic peptides that passed through the membrane were collected. The ultrafiltration membrane was then washed with 200 μL pH 8.2 HEPES (Sigma, Catalog No. H3375) buffer to collect the solution that passed through the membrane, and the peptides from the two ultrafiltrations were combined.

[0055] (5) The ultrafiltered peptide solutions were desalted by passing through a tip column (200 μL) filled with 2 mg HLB filler (Waters, USA), and freeze-dried to obtain a peptide mixture.

[0056] (6) The peptide mixtures were re-dissolved with 20 μL of 0.1% formic acid (Sigma, catalog number V900803) and analyzed by LC-MS / MS. A data-independent (DIA) mass spectrometry acquisition was performed for each sample. The spectrum files obtained by mass spectrometry were used to identify and quantify the peptides, and the protein to which each peptide belongs, the position of the peptide on the protein, and the abundance of the peptide in each sample were obtained. The abundance of the peptides in the lapatinib-treated and untreated groups was calculated by Empirical Bayes t-test to obtain the P value and fold change of each peptide, which respectively represent the significance and fold change of the abundance of the peptide after the addition of lapatinib. For each protein, the peptide with the smallest P value (most significant) among all its peptides is used to represent the protein. In this example, -log 10 Proteins with Pvaue>5 are proteins with changed energy states. Figure 2 A shows the -log of all quantified proteins. 10The volcano plot was made with P value as the ordinate and log2fold change (abbreviated as log2FC) as the abscissa. It can be seen that among all the 5774 proteins quantified under the treatment of 100nM lapatinib, only ERBB2, a known target protein of lapatinib, showed significant changes.

[0057] ERBB2 is a receptor tyrosine kinase bound to the cell membrane surface, which is mainly composed of an extracellular region, a transmembrane region, and an intracellular region (kinase region, non-kinase region), wherein lapatinib acts on the kinase domain of ERBB2. The peptides of ERBB2 identified by analysis are shown in Figure 2B. The horizontal axis represents the protein sequence from the beginning to the end (protein N-terminus to C-terminus), the squares on the horizontal axis represent the kinase domain acted by lapatinib, and the vertical axis represents the multiple change in the abundance of ERBB2 peptides under 100nM lapatinib treatment. It was found that only the peptides located in or very adjacent to this region changed significantly (|log2FC|>0.3&-log 10 Pvalue>2), indicating that this method can determine the binding area of ​​the drug.

[0058] It was further found that at higher lapatinib concentrations (100 μM, 10 μM, 1 μM), the peptides in the ERBB2 kinase domain were more resistant to enzyme cleavage ( Figure 2 C). In addition, we noticed that only ERBB2 was identified as having a change in energy status when the concentration of lapatinib was 100 nM. However, when the concentration of lapatinib was increased, many other kinases such as CHEK2, SLK, RIPK2 and YES1 also had changes in energy status ( Figure 2 D), and most of the peptides that change in these kinases are also located in the kinase domain ( Figure 2 E). This result indicates that lapatinib is prone to cross-reaction with other kinases at high doses, indicating that PELSA can be used to evaluate the cross-reactivity of drugs and then to guide the design and synthesis of drugs.

[0059] In addition, we also noticed that the non-kinase protein PTGES2 also underwent changes in energy status at high lapatinib concentrations ( Figure 2D). We further verified it by Western blotting. The process and conditions were the same as above, except that: a large dish of BT474 cells (cell count was about 5*e7) was suspended in PBS, cell lysis and protein concentration were determined as above, the obtained cell lysate was divided into 8 parts, and equal volumes of different final concentrations of lapatinib (lapatinib dissolved in DMSO) or DMSO were added, so that the final concentration of lapatinib was 100μM, 50μM, 10μM, 1μM, 0.1μM, 0.01μM, 0.001μM and 0, respectively, and incubated at room temperature 25℃ for 30min. After the incubation, trypsin was added at a mass ratio of 1:40 between enzyme and protein, and the enzyme was digested at 37℃ for 1min. After the enzyme digestion was completed, the enzyme was terminated by heating at 95℃, and 1 / 4 of the volume of protein solution 5*loading buffer was added and heated at 95℃ for 5min. Immunoblotting was used to detect the amount of protein remaining after enzyme cleavage. Concentrating gel: 80V, 20min, separation gel 120V, 60min. Transfer: constant current 250mA, 40min. After blocking, PTGES2 primary antibody (Proteintech, USA) was added at a volume ratio of 1:800 and incubated at room temperature for 1h, and then incubated with goat anti-rabbit HRP-IgG secondary antibody (Abcam, UK) at room temperature for 1h. ECL luminescent reagent (Thermo Fisher Scientific, America) and Fusion FX5 chemiluminescent system (VilberInfinit, France) were used to image the remaining protein after enzyme cleavage, and the remaining protein was quantified according to the depth of the band. For the reference protein GAPDH, incubate overnight at 4°C, incubate with rabbit anti-mouse HRP-IgG secondary antibody (Abcam, UK) at room temperature for 1h, and detect by luminescence. Figure 2 As shown in F, with the increase in the concentration of lapatinib, the band becomes darker and darker, indicating that the amount of protein remaining after PTGES2 is cleaved by enzyme is gradually increasing, reaching the maximum value when the concentration of lapatinib reaches 50 μM, indicating that the ability of PTGES2 to resist enzyme cleavage depends on the concentration of lapatinib, further suggesting that PTGES2 may be an off-target protein of lapatinib.

[0060] The above analysis results show that PELSA can identify the binding protein of the ligand with high specificity, and determine the binding area of ​​the ligand by analyzing the changes in the target protein peptide segment; this non-discriminatory target protein screening mode at the omics level can also identify other off-target proteins, such as other kinases and PTGES2 identified in this example, suggesting that this method can be used to evaluate the promiscuousness of drugs, and then provide guidance for drug design and development. In addition, analysis at the peptide level found that only the peptide segment in the ligand binding area has undergone significant changes, suggesting that this method can reveal the area of ​​action of the drug. When treated with different concentrations of ligand, the abundance change value of the target protein has a concentration-dependent change, suggesting that this method can determine the affinity of the ligand and the target protein.

[0061] Example 2 compares LiP-MS and PELSA in the identification of proteins whose energy states change after treatment of HeLa cell lysate with methotrexate (MTX) and SHP099.

[0062] In order to reflect the advantages of the present invention in the identification of proteins whose energy states have changed, this example compares the existing method LiP-MS based on enzyme digestion to identify ligand-bound target proteins and the present invention (PELSA) in parallel to identify proteins whose energy has changed after MTX and SHP099 treated HeLa cell lysate. The target protein of MTX is DHFR, and the target protein of SHP099 is PTPN11. In this example, the process and conditions of PELSA are the same as those of Example 1, except that the cell samples used are derived from HeLa cells, and the ligand molecules used are MTX (Selleck, Article No. S1210) with a final concentration of 10 μM or SHP099 (Selleck, Article No. S8278) with a final concentration of 10 μM. The experimental process of LiP-MS mainly refers to the literature (Piazza I, et al, Nature Communication, 2020, 11 (1): 4200), and the specific implementation steps are as follows (the process and conditions are the same as those of Example 1, except that):

[0063] (1) The cell lysis buffer used was 60 mM HEPES pH 7.5, 150 mM KCl and 1 mM MgCl2 (Piazza I, et al, Nature Communication, 2020, 11(1):4200).

[0064] (2) After the incubation of the cell lysate and the drug, Proteinase K (Sigma, Catalog No. P2308) was added at a ratio of 1:100 (mass ratio) of enzyme to protein, and the enzyme was digested on an oscillator at 25°C, 1000 rpm for 4 min. The mixture was heated at 98°C for 1 min, and then an equal volume of 10% sodium deoxycholate (Sigma, Catalog No. D6750) was added. The mixture was heated at 98°C for 4 min to denature the large protein fragments and obtain a protein solution.

[0065] (3) Add TCEP (Sigma, Catalog No. C4706) with a final concentration of 10 mM and CAA (Sigma, Catalog No. 22790) with a final concentration of 40 mM to the above protein solution, heat at 98°C for 5 min, cool to room temperature, add four times the volume of 60 mM HEPES buffer (pH 8.2), and dilute the concentration of sodium deoxycholate to 1%.

[0066] (4) Lys-C (Wako chemicals) was added at an enzyme to protein ratio of 1:100 (mass ratio) for 4 h, and then trypsin (Promega) was added at an enzyme to protein ratio of 1:50 (mass ratio) for 16 h.

[0067] (5) After the digestion, formic acid (FA) was added to the solution to make the final volume fraction 1.5%. The solution was allowed to stand for 10 min until the sodium deoxycholate precipitate reached equilibrium, and then centrifuged at 20,000 g for 10 min (twice) at room temperature to remove the sodium deoxycholate precipitate.

[0068] (6) The process of desalting, mass spectrometry quantification, software analysis, and data verification is the same as in Example 1. The difference is that when using Spectronaut for identification, the enzyme cutting parameter is set to Trypsin, Semi-specific.

[0069] like Figure 3 A, 3B, if -log 10 Peptides with Pvalue>2 (the part above the horizontal dashed line in the figure) and |log2FC|>0.3 (the part outside the vertical dashed line in the figure) are defined as peptides that respond to the ligand. In the MTX-DHFR system, the DHFR peptides that respond to MTX identified by PELSA are twice that of LiP-MS; in the SHP099-PTPN11 system, the PTPN11 peptides that respond to SHP099 identified by PELSA are 5.25 times that of LiP-MS. In addition, the response amplitude of the DHFR peptides that respond to MTX in PELSA is 4.3 times that in LiP-MS ( Figure 3 C); The response amplitude of the PTPN11 peptide fragment that responds to SHP099 in PELSA is 6.4 times that in LiP-MS ( Figure 3 C). This result shows that compared with LiP-MS, PELSA can identify more peptides of target proteins that respond to ligands, and the response amplitude of these peptides to ligands is much greater than that of target protein peptides that respond to ligands identified by LiP-MS, which also makes PELSA more sensitive in identifying proteins with changed energy states. For example, in this embodiment, GART (Mikkelsen TS et al, Pharmacogenet Genomics, 2011, 21 (10): 679-686), which is involved in the pharmacokinetic process of MTX, was only identified as a protein with changed energy state in PELSA, while GART did not change in LiP-MS ( Figure 3 A).

[0070] This embodiment shows that compared with the existing method LiP-MS, the present invention (PELSA) can produce more peptides responsive to ligand binding and the response amplitude of the responsive peptides is larger, so more ligand-binding proteins can be identified, which also partially explains why the present invention has extremely high sensitivity in the identification of ligand-binding proteins.

[0071] Example 3 PELSA was used to analyze proteins and protein regions whose energy status changed after HeLa and K562 cell lysates were treated with staurosporine, a broad-spectrum kinase inhibitor.

[0072] This study demonstrated that PELSA has a very high sensitivity in identifying proteins with changed energy states through the identification of staurosporine-binding proteins and comparison with the results reported in the literature.

[0073] The experimental process and conditions were the same as those in Example 1, except that K562 and HeLa cell samples were used, and the ligand molecule used in the experimental group was staurosporine (Selleck, catalog number S1421) with a final concentration of 20 μM. Figure 4 As shown in A, after adding staurosporine, a large number of kinases were stabilized in HeLa and K562 lysates as measured by PELSA ( Figure 4 A). If the proportion of kinases in the identified target proteins is limited to 80%, PELSA ultimately identified 121 stabilized kinases in K562 cell lysate (a total of 143 target proteins) and 111 stabilized kinases in HeLa lysate (a total of 135 target proteins). In the published literature, LiP-Quant was able to identify only 9 kinases that responded to staurosporine under the same kinase ratio condition (i.e., 80% or more of the target proteins were kinases). Figure 4B), TPP identified 53 kinases that responded to staurosporine (a total of 60 target proteins were identified). This data shows that PELSA has a very high sensitivity compared with existing methods ( Figure 4 B).

[0074] We further compared the protein and peptide coverage of LiP-Quant, TPP, and PELSA. We found that although LiP-Quant identified more peptides than PELSA ( Figure 4 C) and the protein sequence coverage of the proteome identified by LiP-Quant is generally greater than that of PELSA ( Figure 4 D), but the number of kinases identified by PELSA as responsive to staurosporine (i.e., kinases identified as target proteins) was much greater than that of LiP-Quant (111 vs. 9). Further analysis revealed that the coverage of kinase sequences identified as target proteins by PELSA was significantly less than that by LiP-Quant ( Figure 4 D), indicating that PELSA can identify the bound protein as the target protein even when the sequence coverage is low, while LiP-Quant requires a higher sequence coverage to accurately identify it as the target protein because it contains many invalid full trypsin cleavage peptides.

[0075] Even in the case where TPP(K562) had more protein identifications than PELSA-K562 (7678 vs. 6310) ( Figure 4 C), the number of kinase target proteins identified by PELSA is still 2.28 times that of TPP, which further illustrates the extremely high sensitivity of PELSA in target protein identification. Analysis of the melting points of the kinases identified by TPP and PELSA revealed that TPP discriminated against kinases with very high or very low melting points, resulting in the inability to screen them out, while PELSA had good identification of kinases in various melting point ranges ( Figure 4 E).

[0076] PELSA identified 192 staurosporine target proteins in two cell lines, of which 154 were kinases, accounting for 80% ( Figure 4 F). In addition, PELSA can identify the site of action of staurosporine. Figure 4 As shown in G, more than 92% of the peptides identified by PELSA with significant changes in K562 and HeLa lysates are located in the kinase domain or very close to the kinase domain (less than 10 amino acid residues from the kinase domain). This experimental result shows that PELSA not only has extremely high sensitivity in the identification of ligand-acting proteins, but also can accurately identify the ligand-acting region on the protein.

[0077] Example 4 PELSA was used to analyze proteins and protein regions whose energy status changed after K562 cell lysate was treated with the metabolite folate.

[0078] Different from the strong interaction between lapatinib and ERBB2 (affinity of about 9 nM), folate has a weaker affinity for its binding protein. For example, the literature reports that the dissociation constant between folate and its target protein DHFR is 3-10 μM (Ozaki Y et al., Biochemistry, 1981, 20 (11): 3219-3225). Therefore, we first used folate to explore whether PELSA can be used to analyze the changes in the energy state of proteins caused by the binding of ligands with weaker affinity to proteins. The process and conditions are the same as those in Example 1, except that: K562 cell samples were used, and after repeated freezing and thawing in liquid nitrogen three times, the supernatant was obtained by centrifugation at 500g and 4°C for 10 min, and the endogenous folate was removed using a protein desalting column (Zeba Spin desalting columns, Thermo Fisher Scientific). The collected proteins were purified by Pierce TM The protein concentration was determined by 660nm Protein Assay (Thermo, USA), and the protein concentration was adjusted to 1 mg / mL using a cell lysis buffer, i.e., PBS buffer containing 1% (volume ratio) protease inhibitor cocktail (Sigma, catalog number P8340-5mL). The ligand molecule used was folate (Sigma, catalog number F7879) at a final concentration of 50 μM, and the remaining steps were the same as in Example 1.

[0079] like Figure 5 As shown in A, the stability of DHFR, a known target protein of folate, has undergone the most significant change, and the peptide segment of DHFR change is mapped to its protein structure ( Figure 5 B), and found that the stability of the protein region at the folate binding site changed most significantly. In addition, it was found that the stability of three proteins that can interact with folate analogs, ATIC, MTHFR, and GART, also changed, and their stable sites were located exactly at the binding site of folate analogs ( Figure 5C-5E). P3H1 is a collagen proline hydroxylase. Literature reports that folate can participate in the collagen proline hydroxylation process in vivo (Haustvast J, et al., British Journal of Nutrition, 1974, 32(2): 457-469). Our experimental results show that the hydroxylase domain of P3H1 is stabilized after adding folate ( Figure 5 F), which provides a basis for the involvement of folate in the proline hydroxylation process of collagen.

[0080] Example 5 PELSA was used to analyze proteins and protein regions whose energy status changed after K562 cell lysate was treated with the metabolic molecule leucine.

[0081] The dissociation constants of leucine for its target proteins LARS1 and SESN2 are 95 μM (Kim S, et al, Cell Reports, 2021, 35(4):109301) and 20 μM (Wolfson RL, et al, Science, 2016, 351(6268):43-48), respectively. Therefore, we also used leucine to evaluate whether PELSA can be used to analyze changes in the energy state of proteins caused by the binding of ligands with weaker affinity to proteins.

[0082] The difference from Example 4 is that the ligand molecule used in the experimental group is leucine (Sigma, Catalog No. 61819) with a final concentration of 5 mM, and the remaining steps are the same as Example 4. Figure 5 G, we found that the energy states of leucine's known target proteins LARS1, LARS2, GLUD1 and SENS2 changed most significantly. LARS1 has two leucine binding sites, located in the CD and CP domains, corresponding to the synthetic site and editing site, respectively. We found that the peptide changes in the LARS1 synthetic site (CP marked in the figure) were significantly greater than those in the editing site (CD marked in the figure), while there was no response to the C-terminal domain that did not contribute to leucine binding ( Figure 5 H), the results suggest that PELSA has the ability to distinguish different action sites on the same protein.

[0083] We also found that the stability of SLC1A5, another target protein of leucine, also changed significantly ( Figure 5G). SLC1A5 is a membrane protein composed of intracellular, transmembrane and extracellular regions, and its main amino acid transport function is the Na-dicarboxylate_symporter domain located at residues 54-483. We identified three peptides of SLC1A5, and only the peptide located in this domain (residues 190-212) showed significant changes ( Figure 5 I), which shows that our method can also identify membrane protein targets and locate the action area. Interestingly, we found that leucine can stabilize PPIP5K1 and PPIP5K2 ( Figure 5 G), and only the histidine phosphatase domain of these two proteins was stabilized ( Figure 5 J).

[0084] This example shows that PELSA can also identify weak interactions between metabolites and proteins and accurately point out the binding sites of metabolites. In addition, through the identification of SLC1A5, we found that PELSA also has a good identification effect on membrane target proteins. PELSA also identified some proteins that may interact with leucine, which provides a basis for future functional studies of leucine.

[0085] Example 6 PELSA was used to analyze proteins and protein regions whose energy status changed after HeLa cell lysate was treated with the metabolic molecule diketoglutarate (αKG).

[0086] The process and conditions are the same as those in Example 4. The difference from Example 4 is that the ligand molecule used in the experimental group is αKG (Sigma, catalog number 75890-25g) with a final concentration of 2 mM, and the cell lysate used is derived from HeLa cells. 10 Proteins with P value > 3.4 and log2FC < -0.5 were considered to be stable with 2 mM αKG. Figure 5 K, in HeLa cell fluid treated with 2mM αKG, PELSA identified 40 proteins stabilized by αKG, of which 30 proteins are known αKG-acting proteins; this number represents the largest number of known αKG target proteins identified in a single experiment. Although there are reports of using LiP-MS to identify αKG target proteins in Escherichia coli (Piazza I et al, Cell, 2018, 172 (1-15)), only 2 of the 34 target proteins identified are known αKG-acting proteins. In addition, the two-dimensional stability change diagram of the protein measured by PELSA shows ( Figure 5L), the energy change regions of these known αKG target proteins are located exactly in the binding region of αKG. In summary, this example shows that PELSA has extremely high sensitivity when analyzing the interaction between metabolites with weaker affinity and proteins, and can identify the action region of the metabolites.

[0087] Example 7 PELSA was used to analyze proteins and regions whose energy status changed after antibody treatment of HeLa cell lysate.

[0088] This example will illustrate that PELSA can be used to identify the antigen binding epitope of an antibody by analyzing proteins whose energy states change after antibody treatment of HeLa cell lysate.

[0089] The process and conditions were the same as those in Example 1, except that: HeLa cells were used, and the ligand molecules used were commercial DHFR antibody (Wabways, China, RRID: AB_2877179) and commercial CDK9 antibody (Wabways, China, RRID: AB_2877178); the experimental group was added with 2% (volume fraction) DHFR antibody or 1% (volume fraction) CDK9 antibody, and the control group was added with the same volume of excipient; the -log 10 Proteins with Pvalue>5 were judged as proteins with changed energy status. Figure 6 A is a schematic diagram of identifying antibody-binding antigen epitopes in cell lysate. Figure 6 B (left) is a volcano plot of the protein level obtained by treating HeLa cell lysate with DHFR antibody. Figure 6 B (right) is a volcano plot at the protein level obtained by treating HeLa cell lysate with CDK9 antibody. The energy states of DHFR and CDK9 changed significantly after adding DHFR antibody and CDK9 antibody, respectively, indicating that PELSA can directly screen the antigen protein of the antibody in the cell lysate. Other proteins marked with changes in energy state may be caused by nonspecific adsorption of antibodies.

[0090] Further analysis of the changes in all DHFR peptides identified by PELSA showed that the peptides with energy state changes were located exactly in the known recognition epitopes of the antibody ( Figure 6 C, Figure 6 D). It was observed that for CDK9, two peptides changed in opposite directions. The CDK9 antibody recognized PATTNQTEFERVF located at the tail end of CDK9, and the sequence NPATTNQTEFER had a site that was exactly within the epitope, and less was produced after the addition of the antibody ( Figure 6D), while the sequence NPATTNQTEFERVF (NPxxVF) completely contains the epitope sequence, but the trypsin cleavage site at its N-terminus is outside the epitope. After adding the antibody, the peptide fragment produces more ( Figure 6 D). Further analysis revealed that the intensities of the two peptides identified were very similar when the antibody was added or not ( Figure 6 E), so the reverse change of the peptide can be explained as follows: due to the protective effect of the antibody, the C-terminal R site of the sequence NPATTNQTEFER is more difficult to be cleaved by the enzyme, so less is produced, which in turn leads to more of the sequence NPATTNQTEFERVF (NPxxVF) that should not respond. This result shows that PELSA has a high resolution in identifying antigen epitopes.

[0091] This example shows that PELSA can well identify the interaction between antibodies and proteins and reveal the action sites of antibodies and proteins, and suggests that PELSA can also be used in other protein-protein interaction systems.

[0092] Example 8 PELSA was used to analyze proteins and protein regions whose energy status changed after treating BT474 cell lysate with post-translationally modified peptides.

[0093] Post-translational modification of proteins plays an important role in various life activities. Its regulation of life activities often requires recognition by downstream proteins and recruitment of effector proteins. Therefore, the identification of proteins that recognize post-translational modifications is of great significance to the understanding of the function of post-translational modifications and the study of the mechanism of disease occurrence. Phosphorylated tyrosine-glutamate-glutamate-isoleucine (hereinafter referred to as pYEEI) is known to be recognized by proteins containing SH2 domains. In the following, we will illustrate that PELSA can be used to identify post-translational modification recognition domains by analyzing proteins and protein regions whose energy states change after pYEEI treatment of BT474 cell lysate.

[0094] The process and conditions are the same as those in Example 1, except that: 2 mM phosphatase inhibitor is additionally added to the cell lysis buffer to prevent the added phosphorylated peptide from being dephosphorylated by the active phosphatase in the cell lysate; in order to make the ligand molecule suitable for the analysis of the pulldown experiment so as to facilitate parallel comparison with the experimental results of PELSA, the ligand molecule we used is 100 μM N-terminal biotin-coupled pYEEI (hereinafter abbreviated as Biotin-pYEEI, synthesized by Qiangyao Biotechnology); in order to simultaneously exclude the influence of the phosphate group and YEEI on the entire proteome, two control groups are used in this example, and the ligand molecules added to the control groups are: 100 μM N-terminal biotin-substituted phosphorylated serine-glutamate-glutamate-isoleucine (abbreviated as Biotin-pSEEI, synthesized by Qiangyao Biotechnology) and 100 μM N-terminal biotin-substituted tyrosine-glutamate-glutamate-isoleucine (abbreviated as Biotin-YEEI, synthesized by Qiangyao Biotechnology).

[0095] The pulldown experiment scheme is as follows: BT474 cells are used, and the cell lysis and cell lysate are obtained, and the concentration is determined and adjusted as in Example 1. After the protein concentration of the cell lysate is adjusted to 1 mg / mL, 100 μL of cell lysate is added to Biotin-pYEEI with a final concentration of 100 μM as the experimental group, and two portions of 100 μL are added to Biotin-pSEEI with a final concentration of 100 μM and Biotin-YEEI with a final concentration of 100 μM as the control group, and repeated three times. The cell lysate and the added ligand molecules are incubated at room temperature for 30 minutes. After the incubation, 200 μL of avidin beads (Thermo, USA) are added to each group, and incubated overnight at 4°C. The next day, wash four times with 400 μL of washing solution (1% cocktail, 1% phosphatase inhibitor and 0.5% NP40 in PBS solution), and then wash four times with 400 μL of cell lysis buffer (1% cocktail, 1% phosphatase inhibitor in PBS solution). Then, the protein was eluted with 100 μL of HEPES buffer (pH 8.2) containing 8M guanidine hydrochloride, and the process was repeated twice. TCEP and 40 mM CAA were added to the eluted protein at a final concentration of 10 mM, and the protein was fully alkylated at 95°C for 5 min. The protein solution was transferred to an ultrafiltration tube, centrifuged at 14,000 g for 30 min, and the membrane permeate was removed. The ultrafiltration membrane was washed twice with 200 μL of 10 mM ammonium bicarbonate (NH4HCO3) buffer, and the permeate was removed. 100 μL of 10 mM NH4HCO3 was added to resuspend the protein sample retained on the membrane, and 2 μg of trypsin (Promega) was added for overnight enzymatic hydrolysis. The next day, the ultrafiltration tube was centrifuged at 14,000 g for 50 min to collect the peptides obtained by enzymatic hydrolysis, and the ultrafiltration tube membrane was washed with 100 μL of NH4HCO3, and the permeate was collected to recover the residual peptides. The enzymatic hydrolyzate and the second membrane washing solution were combined and freeze-dried. The mass spectrometry quantification, software analysis, and data verification process are the same as in Example 1.

[0096] Figure 7 A is a schematic diagram of identifying tyrosine phosphorylation recognition domains in cell lysates. Using YEEI as the control group, the Pvalue (pYEEI / YEEI) was obtained by Empirical Bayes t-test; using pSEEI as the control group, the Pvalue (pYEEI / pSEEI) was obtained by Empirical Bayes t-test. The two Pvalues ​​were logarithmized and scatter plotted. If the -log 10 Pvalue(pYEEI / YEEI)>3.1;log2FC(pYEEI / YEEI)<0;-log 10Proteins with Pvalue (pYEEI / pSEEI)>3.1 and log2FC (pYEEI / pSEEI)<0 were defined as proteins whose energy state was reduced, that is, proteins stabilized by the added ligand. Finally, 28 proteins stabilized by pYEEI were screened. Among these 28 proteins, 9 contained SH2 domains and 8 were calcium-related proteins ( Figure 7 B). In the pulldown experiment, due to the strong washing intensity, no proteins containing SH2 domain were screened out ( Figure 7 C). PELSA also enabled the identification of the recognition domain of pYEEI: Figure 7 D and Figure 7 As shown in Figure E, only the peptides located in the SH2 domain were stabilized after the addition of pYEEI, while the abundance of peptides in other parts remained unchanged. In addition, the calcium ion-related proteins identified were only stabilized in specific EF-hand domains ( Figure 7 F).

[0097] The above results indicate that PELSA can identify proteins and domains that are post-translationally modified by identifying proteins and protein regions whose energy states change after treating cell lysates with post-translationally modified peptides.

[0098] Example 9 PELSA analysis of proteins and protein regions whose energy status changes after HeLa cell lysate is treated with metal ions.

[0099] In this example, we investigated whether PELSA is applicable to small metal ion binding to proteins leading to changes in the protein energy state.

[0100] The process and conditions were the same as those in Example 1, except that: HeLa cells were used and the cell lysis buffer used was the cell lysis buffer of Example 1 with the addition of 2 mM sodium ethylenediaminetetraacetate (EDTA, purchased from Sigma); after obtaining the cell lysate in the manner of Example 1, the added EDTA was removed using a protein desalting column (Zeba Spin desalting columns, Thermo Fisher Scientific), and the protein desalting process was repeated twice; the ligand molecule added to the experimental group was ZnCl2 (Sigma, catalog number 450111-10G) with a final concentration of 30 μM; the -log 10 Proteins with Pvalue>3 and log2FC<-0.5 were considered to be stabilized by zinc ions.

[0101] Figure 8As shown in A, a large number of metal ion binding proteins are stabilized by zinc ions; among all the 280 proteins identified to be stabilized by zinc ions, more than 66% of the proteins, i.e., 185 proteins, are known metal ion binding proteins, while in the entire identified proteome, the proportion of metal ion binding proteins is only 19%, indicating that PELSA can screen out metal ion binding proteins by identifying proteins whose energy states change after the addition of zinc ions. Literature reports that zinc ions can bind to the EF-hand motif of calcium ion binding proteins (Tsvetkov PO, et al, Front Mol Neurosci, 2018, 11: 459), and can also bind to magnesium ion binding proteins and occupy the binding sites of magnesium ions (Dudev T, et al., Chemical Reviews, 2003, 103 (3): 773-787), suggesting that these divalent metal ions have promiscuous properties for metal ion binding proteins. Consistent with literature reports, we found that among the 185 metal ion binding proteins stabilized by zinc ions, 112 were zinc ion binding proteins and 73 other metal ion binding proteins ( Figure 8 B) Among the 73 other metal ion binding proteins, 25 are calcium ion binding proteins, 20 are magnesium ion binding proteins, 15 are iron ion binding proteins, 9 are manganese ion binding proteins and 6 are other metal ion binding proteins ( Figure 8 C) Among the 112 zinc-binding proteins, 60 proteins contain zinc finger structures that bind zinc ions ( Figure 8 C). By analyzing these proteins containing zinc finger structures, we found that the median distribution of log2FC of peptides located in the zinc finger structure was significantly smaller than the median distribution of log2FC of peptides outside the zinc finger structure ( Figure 8 D); Analysis of a single protein containing a zinc finger structure also revealed that only the peptide located at the zinc finger structure was significantly stabilized ( Figure 8 E), these results show that PELSA can determine the binding site of zinc ions. In addition, for proteins without zinc finger structures, for example, LIMA1 protein contains a LIM zinc ion binding domain. In this experiment, three peptides in this domain were quantified ( Figure 8 F), the peptide with the largest change factor is the peptide that directly binds to zinc ions, while the other two peptides that are not directly involved in zinc ion binding have very small change factors (|log2FC|<0.3, Figure 8 G), which demonstrates that PELSA has extremely high accuracy in locating binding sites.

[0102] Analyzing the calcium binding proteins identified, 20 of the 27 proteins contained EF-hand / EH motif (calcium binding motif). Like the proteins containing zinc finger structures, the median of log2FC distribution of peptides located in EF-hand / EH motif is significantly smaller than the median of log2FC distribution of peptides outside EF-hand / EH motif, indicating that zinc ions act on the EF-hand / EH motif ( Figure 8 H). In addition, for the 9 proteins containing iron-binding domains, the median distribution of log2FC of peptides located in the iron-binding domains was significantly lower than that of peptides outside the iron-binding domains, indicating that zinc ions act on the iron-binding regions of these iron-binding proteins ( Figure 8 I).

[0103] If the binding of a ligand to a protein causes the protein to dissociate from its original complex, it will cause the partner protein in the complex to destabilize. We found that several proteins containing IQ-motifs were destabilized, i.e., -log 10 Pvalue>6; log2FC>0 (Figure 8J), and the destabilized peptide segment is located in the vicinity of the IQ-motif ( Figure 8 K). IQ-motif is a known binding site for EF-hand motif, and EF-hand motif can bind to zinc ions ( Figure 8 H), so the destabilization of IQ-motif may be due to the dissociation of IQ-motif and EF-hand motif caused by the binding of EF-hand motif and zinc ion. IQ-motif and EF-hand motif are the interface of protein-protein interaction. This result suggests that PELSA can be used to analyze the changes in energy state caused by the assembly and dissociation of protein complexes in cells and reveal the binding interface of proteins in the complex.

[0104] We also noticed that a series of proteins PSMC1-6, components of the 26S proteasome regulatory subunit, were destabilized ( Figure 8 J). PSMC1-6 all contain a P-Loop-NTPase domain located at the binding interface of the PSMC1-6 complex. The results of PELSA showed that only the peptides located in this domain were significantly destabilized ( Figure 8 L), which may be due to the dissociation of the 26S proteasome regulatory subunit by zinc ions, leading to the destabilization of the PSMC1-6 protein interaction interface. This result further suggests that this method can be used to study the dynamic changes of protein complex assembly and dissociation.

[0105] Example 10 PELSA based on other enzymes analyzes proteins whose energy status changes after HeLa cell lysate is treated with methotrexate (MTX).

[0106] To evaluate whether other enzymes can be used to analyze proteins with altered energy states following the PELSA protocol, we tested trypsin and two other enzymes with different cleavage site specificities, chymotrypsin (purchased from Sigma, Cat. No. C3142) and proteinase K (also referred to as PK, purchased from Sigma, Cat. No. P2308), in parallel to analyze proteins with altered energy states after MTX treatment of HeLa cell lysates. The main cleavage site of chymotrypsin is at the N-terminus of aromatic amino acids, while proteinase K has a wide range of cleavage sites.

[0107] The implementation steps of Trypsin-PELSA are different from those of Example 1 in that: HeLa cell samples are used, the ligand molecule added to the experimental group is MTX with a final concentration of 10 μM (dissolved in DMSO, the mother solution concentration is 1 mM; purchased from Selleck, item number S1210), and the experimental group and the control group are repeated four times, incubated at room temperature for 30 minutes, and trypsin is added at a ratio of 1:2 (mass ratio) of enzyme to protein, and the enzyme is cut at 37°C and 1000 rpm on an oscillator for 1 minute, and 165 μL of pH 8.2 HEPES buffer containing 8M guanidine hydrochloride is added to terminate the enzymatic hydrolysis. The remaining experiments, mass spectrometry quantification, software analysis, and data verification processes are the same as in Example 1.

[0108] The implementation steps of Chymotrypsin-PELSA are different from those of Trypsin-PELSA in that trypsin is replaced by chymotrypsin; the enzyme digestion conditions are 25°C, 1000 rpm on an oscillator for 1 min; when Spectronaut is used to search the library, the digestion parameters set the enzyme cutting sites to: F, W, Y, L, M, and the remaining steps are the same as Trypsin-PELSA.

[0109] The implementation steps of Proteinase K-PELSA are different from those of Trypsin-PELSA in that trypsin is replaced by proteinase K; the enzyme digestion conditions are 25°C, 1000 rpm on an oscillator for 1 min; and when Spectronaut is used to search the library, the digestion parameter sets the enzyme cleavage site to trypsin, unspecific. The remaining steps are the same as Trypsin-PELSA.

[0110] like Fig. 9 As shown in A, Trypsin-PELSA finally identified 69,245 peptides, while the number of peptides identified by Chymotrypsin-PELSA and Proteinase K-PELSA was much less than that of Trypsin-PELSA (18,027 and 28,702, respectively). Correspondingly, the number of proteins identified by Trypsin-PELSA (5,487) was also much greater than that of Chymotrypsin-PELSA (2,710) and Proteinase K-PELSA (1,937) ( Fig. 9 B). The proteins identified by the trypsin group can cover most of the proteins identified by the proteinase K group and the chymotrypsin group ( Fig. 9 B). This is mainly because the tryptic peptides produced by trypsin are more conducive to mass spectrometry identification than the peptides produced by other enzymes. In terms of protein identification with energy state changes, since DHFR, a known binding protein of MTX, is a protein with high abundance, the above three enzymes can cover this protein and thus can screen it out ( Fig. 9 C) This example shows that PELSA is not limited to trypsin, and other specific enzymes and non-specific enzymes can also be used to identify proteins with changed energy states, but there may be a problem of a small number of protein and peptide identifications.

[0111] Example 11 PELSA based on dimethyl labeling quantification analyzed the proteins and regions whose energy status changed after HeLa cell lysate was treated with three heat shock protein inhibitors.

[0112] The implementation steps are as follows:

[0113] (1) HeLa cells were used, and the cell disruption, protein extraction and quantification steps were the same as in Example 1. Six groups of 50 μL of cell lysate were placed in EP tubes, of which three groups were added with 100 μM geldanamycin, 100 μM tanespimycin, and 100 μM ganetespib (the stock solution concentration was 10 mM; all dissolved in DMSO solution, all purchased from Selleck), and the other three groups were added with an equal amount of DMSO. The cells were incubated at room temperature of 25°C for 30 min. After the incubation, trypsin was used at a ratio of 1:2 to protein mass, and the enzyme digestion was performed at 37°C for 1 min, and the enzyme digestion was terminated by heating at 100°C for 5 min.

[0114] (2) Three times the volume of sodium dihydrogen phosphate buffer (pH 6.5) containing 8 M guanidine hydrochloride was added to the above protein solution, and a final concentration of 10 mM TCEP and a final concentration of 40 mM CAA were added and heated at 95°C for 5 min. After cooling to room temperature, the sample was further transferred to a 10 KDa ultrafiltration tube and centrifuged at 14000 g for 50 min to collect the enzymatic peptides. The ultrafiltration membrane was then washed with 200 μL sodium dihydrogen phosphate buffer (pH 6.5), and the peptides from the two ultrafiltrations were combined.

[0115] (3) Dimethyl labeling: 16 μL of 4% deuterated formaldehyde (Sigma, Catalog No. 596388) and 16 μL of 0.6 M sodium cyanoborohydride (Sigma, Catalog No. 156159) were added to the peptides collected from the drug group as medium labeling; 16 μL of 4% formaldehyde (Sigma, Catalog No. 252549) and 16 μL of 0.6 M sodium cyanoborohydride were added to the control group as light labeling, and the reaction was carried out at 30°C for 1 hour. After the reaction, 10 μL of 10% ammonia water (Sigma, Catalog No. 338818) was added and reacted for 30 minutes. After labeling, the peptides of the drug group and the control group were mixed in equal mass.

[0116] (4) The dimethyl labeled solution was acidified by adding 4.5 μL trifluoroacetic acid (Sigma, Catalog No. T6508), desalted using a tip column (specification: 200 μL) filled with 2 mg HLB filler (Waters, USA), and lyophilized to obtain a peptide mixture.

[0117] (5) The peptide mixture was reconstituted with 30 μL of 0.1% formic acid, and 1 μg was loaded. Each sample was subjected to two LC-MS / MS analyses in data-dependent data acquisition mode (DDA), so each peptide had two quantitative results.

[0118] (6) The spectrum files obtained in the DDA acquisition mode were analyzed using Maxquant software (Cox, Germany) to obtain the protein to which the small peptides belong, the position of the small peptides on the protein, and the ratio of the abundance of the small peptides in the experimental group and the control group (fold change, i.e., FC).

[0119] In this example, three representative heat shock protein inhibitors were selected, namely, geldanamycin and tanespimycin, ansamycin heat shock protein inhibitors containing benzoquinone groups, and ganetespib ( Fig.10A), where geldanamycin and tanespimycin differ only in the circled structural part. The peptide with the second largest change (i.e., the peptide with the second largest |log2FC| among all the peptides quantified for a given protein) is used to represent the protein. The results of the two-shot quantification of mass spectrometry are shown in Figure 2. Fig.10 B. If the two-shot quantitative results |log2FC|>1.4 are considered as proteins with changed energy status, heat shock proteins HSP90AB1, HSP90AA1, HSP90A1, and HSP90ABP are well screened out, proving that PELSA based on dimethyl labeling quantification can also well identify proteins with changed energy status. In addition, it was found that the heat shock protein TRAP1 located in mitochondria was only identified as a protein with changed energy status in ganetespib.

[0120] HSP90 protein is mainly composed of three domains, N-terminal ATP binding domain, middle domain, and C-terminal domain. Among them, geldanamycin, tanespimycin and ganetespib all act on the N-terminal ATP binding domain. Analyze the fold change (FC) of the abundance of peptides in different domains. Fig.10 As shown in Figure C, taking geldanamycin as an example, only the peptide fragment of the N-terminal domain, i.e., the drug binding region, showed a significant abundance change after PELSA analysis, further proving that PELSA can identify protein regions where energy states have changed.

[0121] In addition to known target proteins, PELSA also identified many unknown off-target proteins. For geldanamycin, PELSA identified several proteins in the PRDX family that were destabilized, i.e., log2FC>1.4 ( Fig.10B). Literature reports that geldanamycin can produce reactive oxygen species (ROS) leading to severe liver toxicity (Clark et al, Free Radical Biology & Medicine, 2009, 1440-1449), and PRDX family proteins can scavenge ROS and protect cells when cells are subjected to oxidative stress. The destabilization of PRDX family proteins indicates that the structure of PRDX family proteins is destroyed at high geldanamycin concentrations, which also provides a possible explanation for the liver toxicity mechanism of geldanamycin. For the small molecule tanespimycin, which has a similar structure to geldanamycin, PELSA identified off-target proteins PRDX5 and NQO1 shared with geldanamycin, of which NQO1 has been reported to metabolize ansamycin heat shock protein inhibitors (Reigan PD, et al, Molecular Pharmacology, 2011, 79(5): 823-832). In addition, PELSA also identified two previously unreported off-target proteins of ganetespib, MAT2A and AKR1C2 ( Fig.10 B) To further verify that the two proteins can bind to ganetespib, we purified the two proteins and then used the thermal shift method to see whether the two proteins interacted with ganetespib. Fig.10 As shown in D, after the addition of ganetespib, the thermal melting temperatures of MAT2A and AKR1C2 were significantly increased, confirming the binding between AKR1C2 and MAT2A and ganetespib. In addition, the results of thermal migration showed that there was also binding between AKR1C2 and geldanamycin, and the stabilizing effect of geldanamycin on AKR1C2 was less than that of ganetespib ( Fig.10 D). Similarly, in the PELSA results, geldanamycin also had a smaller stabilizing effect on AKR1C2 than ganetespib ( Fig.10 B).

[0122] The above results show that the quantitative PELSA using dimethyl labeling and the screening strategy of two peptide segments can accurately determine the proteins with changed energy states and distinguish the target proteins of inhibitors with similar and different structures. The thermal shift experiment of in vitro protein purification proves that the unknown target proteins identified by PELSA have high credibility. The construction of this target protein space has important guiding significance for understanding the hepatotoxicity of ansamycin heat shock protein inhibitors and the new use of ganetespib.

[0123] Example 12 PELSA evaluates the local affinity of heat shock protein inhibitors to their target proteins.

[0124] The process and conditions are the same as those in Example 1, except that the cell lysate is derived from HeLa cells; 14 portions of 50 μL cell lysate are divided into an experimental group and a control group, with 7 portions of cell lysate in each group. Different concentrations of geldanamycin are added to the experimental group to make the final concentrations 100 μM, 10 μM, 1 μM, 100 nM, 10 nM, 1 nM, and 0.1 nM (geldanamycin dissolved in DMSO), and an equal volume of DMSO is added to the control group. Trypsin is added at an enzyme to protein mass ratio of 1:2, and enzyme digestion is carried out at 37°C for 1 min. The subsequent experimental steps, mass spectrometry quantification, and software analysis are the same as in Example 11. Tanespimycin and ganetespib are treated with reference to geldanamycin.

[0125] Fig.11 As shown in A, taking ganetespib as an example, only the peptides located in the N-terminal domain of HSP90 protein increase in abundance with the increase of drug concentration and then tend to be stable. The affinity of heat shock protein and three heat shock protein inhibitors was further calculated based on the change of these peptides with the change of drug concentration. The peptides of heat shock protein with at least 12 quantitative values ​​(a total of 14 quantitative values) were fitted to the four-parameter logarithmic equation Y = Bottom + (Top-Bottom) / (1 + 10^(LogEC 50 -X)*HillSlope)); using Pearson correlation coefficient R 2 To evaluate the fit between the original data and the equation, the good fit, i.e. R 2 Peptides with a value greater than 0.9 were extracted as candidate peptides, and the change in abundance of candidate peptides under the highest ligand concentration was required to be 30% or more. The median of the change in the multiple of all peptides of the same protein that met the conditions was taken as the change in the multiple of the protein under a certain ligand concentration, i.e., the value corresponding to the four-parameter logarithmic equation Y. X still represented the ligand concentration. The four-parameter logarithmic equation was fitted with Prism software again to obtain EC 50 ( Fig.11 B). Fig.11 As shown in C, the protein was purified and then the affinity (K) between the three inhibitors and HSP90AA1 was measured using microscale thermophoresis (MST). d ). The affinity K measured by MST d EC calculated with PELSA 50 Very close.

[0126] The above results show that the affinity calculated by PELSA is consistent with the affinity measured by the classical affinity determination method (such as MST used in the present invention). In addition, this method can also obtain affinity data at the peptide level, which will help understand the interaction between ligands and proteins.

[0127] Example 13 compares the response amplitude of a peptide segment containing two cleavage sites that can reflect the stability of a protein region and a peptide segment containing one cleavage site that can reflect the stability of a protein region to changes in the energy state of the protein.

[0128] To demonstrate the superiority of peptides containing two cleavage sites that reflect the stability of the protein region in responding to changes in the energy state of the protein, we denatured the large protein fragments remaining after PELSA cleavage with a denaturant and then performed complete trypsin cleavage to compare the response of this part of the peptide to geldanamycin binding with the peptide produced by PELSA one-step cleavage.

[0129] The specific implementation steps are as follows:

[0130] 1) The cell sample was derived from HeLa cells. The cell disruption, protein extraction and protein concentration quantification steps were the same as in Example 1. The concentration of the obtained cell lysate was adjusted to 1 mg / mL. 50 μL was taken into an EP tube and geldanamycin (the mother solution concentration was 10 mM, geldanamycin was dissolved in DMSO) with a final concentration of 100 μM was added as the experimental group. Another 50 μL of cell lysate was added with an equal volume of DMSO as the control group. Incubate at room temperature 25°C for 30 minutes. After the incubation, trypsin was added at a ratio of trypsin to protein mass of 1:2, and enzyme digestion was performed at 37°C for 1 minute. The enzymatic hydrolysis was terminated by heating at 100°C for 5 minutes.

[0131] 2) To the above protein solution, three times the volume of sodium dihydrogen phosphate buffer containing 8M guanidine hydrochloride was added, and TCEP with a final concentration of 10mM and CAA with a final concentration of 40mM were added and heated at 95°C for 5min. After cooling to room temperature, the sample was further transferred to a 10KDa ultrafiltration tube and centrifuged at 14000g for 50min to collect the enzymatic peptides. The ultrafiltration membrane was then washed with 200μL sodium dihydrogen phosphate buffer, and the peptides obtained from the two ultrafiltrations were combined to obtain a peptide containing two enzyme cleavage sites that can reflect the stability of the protein region.

[0132] 3) Wash the residual guanidine hydrochloride on the ultrafiltration membrane with 200 μL pH 8.2 HEPES buffer, centrifuge at 14000g for 40 minutes, remove the filtrate, add 100 μL HEPES buffer to resuspend the large protein fragments on the ultrafiltration membrane, add 2 μg trypsin (Promega), and enzymolyze at 37°C for 16 hours. After the enzymolysis is completed, centrifuge at 14000g for 50 minutes, collect the enzymatic peptides, wash the ultrafiltration membrane with 200 μL pH8.2 HEPES buffer, and combine the peptides from the two ultrafiltrations to obtain a peptide containing a cleavage site that can reflect the stability of the protein region.

[0133] 4) Dimethyl labeling, acidification and desalting, and mass spectrometry loading. The peptide segment containing two enzyme cleavage sites that can reflect the stability of the protein region and the peptide segment containing one enzyme cleavage site that can reflect the stability of the protein region were subjected to dimethyl labeling, acidification and desalting, mass spectrometry quantification, and software analysis according to the steps described in Example 11.

[0134] Geldanamycin mainly acts on the N-terminal ATP binding domain of the heat shock protein (HSP90) family, reducing the energy of this domain. Fig.12 As shown, we found that among the three quantified HSP90 proteins, the change fold of the peptide segment containing two N-terminal domains that can reflect the protein regional stability cleavage sites (i.e., the cut-off part) was significantly greater than the change fold of the peptide segment containing one N-terminal domain that can reflect the protein regional stability cleavage site (i.e., the remaining part). This experimental result also proves that the present invention (i.e., detecting peptide segments containing two cleavage sites that can reflect the protein regional stability) is more sensitive to changes in energy status than traditional methods.

Claims

1. A method for detecting a protein whose energy state changes, characterized in that: The method comprises the following steps: A. Mix two or three or more groups of protein solutions in different energy states to be compared with protease and incubate for 0.5-60 min, with the mass ratio of enzyme to protein sample being between 1:1-1:50, so that the protein undergoes destructive enzymatic cleavage, directly generating small peptides containing two enzymatic cleavage sites that can reflect the stability of the protein region and are suitable for bottom-up mass spectrometry analysis; one of the protein solutions is a baseline control group, which is a protein solution whose energy state has not changed; The rest are experimental groups, which are protein solutions with changed energy states; the bottom-up method refers to from peptides to proteins, and the molecular weight of the small peptides is < 5KDa; B. Separating the small peptide fragments and large protein fragments produced in step A; the molecular weight of the large protein fragment is ≥10KDa; C. Use mass spectrometry to quantify and analyze the abundance of the obtained small peptides, the proteins to which the small peptides belong, and the positions of the small peptides on the proteins; D. By analyzing the difference in abundance of small peptides in the experimental and control group samples, we can determine the proteins whose energy status has changed; E. Determine the subprotein structural region where the energy state changes by analyzing the position of the small peptide segments whose abundance changes in the corresponding proteins.

2. The method according to claim 1, characterized in that: The different energy states of the protein include changes in energy states caused by one or more of the following ways: A. Changes in the energy state of a protein caused by the interaction between a ligand and a protein; the ligand comprises one or more of a drug molecule, a metabolite in a human or animal body, a plant extract, a nucleic acid molecule, a metal ion, a peptide, an antibody, or a protein; B. Changes in protein energy status caused by post-translational modifications of proteins; C. One or more of the following: thermal stimulation, osmotic pressure change, denaturant stimulation, oxidative stimulation, and disease-induced changes in protein energy state.

3. The method according to claim 1, characterized in that: The protein solution includes a single protein solution containing one protein or a mixed protein solution containing two or more proteins; the mixed protein solution includes a cell or tissue extract derived from humans, animals, plants or bacteria; Protein extraction should be carried out using a mild extraction method including liquid nitrogen freeze-thaw extraction, liquid nitrogen grinding extraction and homogenization extraction; if the extraction process uses an extraction buffer, the use of surfactants or denaturants that destroy the protein conformation should be avoided so that the protein can maintain its conformation to be tested; the protein to be tested exists in the form of free protein and / or immobilized protein.

4. The method according to claim 1, characterized in that: The protein solutions in different energy states are placed in their conformations to be tested, and the same enzyme cleavage conditions are used. Enzymes are added according to the mass ratio of enzyme to protein, so that proteins in different energy states have different enzyme cleavage degrees, and at the same time, most proteins should be able to produce small peptides directly used for mass spectrometry identification; the enzyme is one or more of trypsin, glutamyl protein endonuclease, thermolysin, proteinase K and other site-specific or non-site-specific enzymes; the mass ratio of the enzyme to the protein used should be between 1:1-1:50; at the same time, the enzyme cleavage time should be adjusted to 0.5-60 min; and the appropriate enzyme cleavage temperature is selected according to the temperature range in which different enzymes maintain activity.

5. The method according to claim 4, characterized in that: In the presence of 1% to 2% by volume of a protease inhibitor, the mass ratio of the enzyme to the protein used should be between 1:1 and 1:

10.

6. The method according to claim 1, characterized in that: The method of separating small peptide fragments and large protein fragments includes using one or more of the differences in molecular weight, hydrophilicity, and thermal stability to separate; The peptide fragments cleaved by the enzyme are quantified in the bottom-up analysis mode of mass spectrometry. The mass spectrometry data acquisition modes include data-dependent acquisition (DDA) and data-independent acquisition (DIA); the quantification methods include label-free quantification and / or labeled quantification.

7. The method according to claim 6, characterized in that: The labeling quantification is selected from one or more of dimethyl labeling quantification, iTRAQ labeling quantification, TMT labeling quantification, and TMTpro labeling quantification.

8. The method according to claim 1, characterized in that: The mass spectrometry quantification and analysis refers to importing the original spectrum file generated by the mass spectrometry into the search library software for analysis to obtain the quantitative information of the small peptide segment, the protein information to which the small peptide segment belongs, and the position information of the small peptide segment on the protein; the search library software includes one or more of Maxquant (Cox, Germany), MSFragger (Alexey, USA), and Spectronaut (Biognosys, Switzerland).

9. The method according to claim 1, characterized in that: The criteria for determining the protein whose energy state has changed include the difference in the difference peptide segments contained in the protein in the sample -log 10 The size of the P value, the size of the peptide difference fold |log2 fold change|, the number of differential peptides N contained in the protein, and whether the peptide difference fold changes in a dose-dependent manner with the concentration of the added ligand; The method of obtaining the significance of the difference of the differential peptides includes: performing a significance test on the quantitative values ​​of the peptides in the experimental group and the control group, and obtaining the P value as an indicator of the significance of the difference between the peptides in the experimental group and the control group, including -log 10 Proteins with a Pvalue > 2 to 5 peptides were considered to have a change in their energy state; The methods for obtaining the difference fold of differential peptides include: directly obtaining the difference fold of peptide abundance between the experimental group and the control group by using the database search software, obtaining the difference fold by using the significance test such as Empirical Bayes t-test or Student's t-test, and the protein containing the peptide with |log2 fold change| > 0.3~3 is considered to have a change in the energy state of the protein; The processing method of the number of differential peptide changes includes: sorting all peptides in each protein according to the difference significance or difference multiple, defining the peptide with the largest difference significance or difference multiple as the peptide with the first largest change in the protein, the second largest peptide as the peptide with the second largest change in the protein, and so on for the third and fourth largest changes; taking the difference significance or difference multiple of the first largest change peptide or the second largest change peptide or the third or fourth largest change peptide as the change value of the protein, and the difference significance -log 10 Proteins with P value > 2~5 or log2 fold change> 0.3~3 are considered to have different energy states. Proteins with different energy states determined by this method contain 1, 2, 3, or 4 proteins that meet -log 10 Peptides with P value > 2~5 or |log2 fold change| > 0.3~3; The criterion for measuring whether the change fold of peptide abundance changes in a dose-dependent manner with the concentration of added ligand includes: using the change fold of peptide obtained by the above method at different ligand concentrations and the concentration of ligand as variables for fitting the four-parameter logarithmic equation, and using the Pearson correlation coefficient R 2 Evaluate the degree of fit between the original data and the equation. 2 If the value is >0.75~0.95, the peptide segment is considered to have a dose-dependent change with the concentration of the added ligand, and the protein to which the peptide segment belongs is considered to be the active protein of the ligand; The protein whose energy state has changed is determined based on one or any combination of two or more of the above criteria.

10. A method for detecting the affinity between a ligand and a protein, characterized in that: The method comprises the following steps: A. A series of ligands with different final concentrations are mixed and incubated with the protein solution respectively; one of the different final concentrations is a blank point without adding ligand as a control group, and the rest are experimental groups; B. After the incubation, the protein solution is incubated with the protease under non-denaturing conditions for 0.5-60 min, with the mass ratio of enzyme to protein being 1:1-1:50, so that the protein undergoes destructive enzymatic cleavage, directly generating a large number of small peptides containing two cleavage sites that can reflect the regional stability of the protein and are suitable for bottom-up mass spectrometry analysis; the bottom-up refers to from peptide to protein, and the molecular weight of the small peptide is < 5KDa; C. Separating the small peptide fragments produced in step B from the large protein fragments; the molecular weight of the large protein fragments is ≥10KDa; D. Use mass spectrometry to quantify and analyze the abundance of the obtained small peptides, the proteins to which the small peptides belong, and the locations of the small peptides on the proteins; E. Calculate the local affinity between protein and ligand, i.e., the half effective concentration (EC) according to the abundance of small peptide fragments in samples treated with different ligand concentrations and the concentration of ligand. 50 ), where the calculation equation is a four-parameter logarithmic equation: Y=Bottom+(Top-Bottom) / (1+10^(LogEC 50 -X)*HillSlope), Y is the ordinate representing the change multiple of peptide abundance in the experimental group and the control group, X is the abscissa representing different ligand concentrations, Bottom and Top are the stable values ​​of the lower and upper ends of the curve corresponding to the four-parameter logarithmic equation, and the unit is the same as Y. Hill Slope refers to the absolute value of the maximum slope of the curve, i.e., the midpoint of the curve. EC 50 is the half effective concentration required for calculation, EC 50 The smaller the value, the stronger the affinity between the ligand and the protein region to which the peptide belongs; The series is 3 or more.

11. The method according to claim 10, characterized in that The series is 5 or more.

12. The method according to claim 10, characterized in that: Ligands include one or more of drug molecules, in vivo metabolites, plant extracts, nucleic acid molecules, metal ions, peptides, antibodies, proteins, or other substances that can interact with proteins.

13. The method according to claim 10, characterized in that: The protein solution includes a single protein solution containing one protein or a mixed protein solution containing two or more proteins; the mixed protein solution includes a cell or tissue extract derived from humans, animals, plants or bacteria; Protein extraction should adopt mild extraction methods including liquid nitrogen freeze-thaw extraction, liquid nitrogen grinding extraction and homogenization extraction; if the extraction process uses extraction buffer, it should avoid using surfactants or denaturants that destroy protein conformation so that the protein can maintain its conformation to be tested; the protein to be tested exists in the form of free protein and / or immobilized protein.

14. The method according to claim 10, characterized in that: The enzymes are added to the ligand groups and control groups treated with multiple ligand concentrations according to the mass ratio of the enzyme to the protein, so that the protein bound to the ligand and the protein not bound to the ligand have different degrees of enzyme cleavage, and at the same time, most proteins should be able to produce small peptides directly used for bottom-up mass spectrometry identification; the enzymes include one or more of trypsin, glutamyl protein endonuclease, thermolysin, proteinase K and other site-specific or non-site-specific enzymes; the mass ratio of the enzyme to the protein used should be between 1:1-1:50; at the same time, the enzyme cleavage time should be adjusted to 0.5-60 min; and the appropriate enzyme cleavage temperature is selected according to the temperature range in which different enzymes maintain their activity.

15. The method according to claim 14, characterized in that: In the presence of 1% to 2% by volume of a protease inhibitor, the mass ratio of the enzyme to the protein used should be between 1:1 and 1:

10.

16. The method according to claim 10, characterized in that: The method of separating small peptide fragments and large protein fragments includes using one or more of the differences in molecular weight, hydrophilicity, and thermal stability to separate; The peptide fragments cleaved by the enzyme are quantified in the bottom-up analysis mode of mass spectrometry. The mass spectrometry data acquisition modes include data-dependent acquisition (DDA) and data-independent acquisition (DIA); the quantification methods include label-free quantification and / or labeled quantification.

17. The method according to claim 16, characterized in that: The labeling quantification is selected from one or more of dimethyl labeling quantification, iTRAQ labeling quantification, TMT labeling quantification, and TMTpro labeling quantification.

18. The method according to claim 10, characterized in that: The mass spectrometry quantification and analysis refers to importing the original spectrum file generated by the mass spectrometry into the search library software for analysis to obtain the quantitative information of the small peptide segment, the protein information to which the small peptide segment belongs, and the position information of the small peptide segment on the protein; the search library software includes one or more of Maxquant (Cox, Germany), MSFragger (Alexey, USA), and Spectronaut (Biognosys, Switzerland).

Citation Information

Patent Citations

  • Novel high-efficiency protease activity detecting method

    CN103149185A

  • Method for detecting differentially-expressed protein

    CN103776891A

  • Protease substrate screening method based on solid-loaded mixed protein as screening database

    CN104419746A

  • Method for detecting conformational changes of proteins by mass spectrometry technology

    CN107219292A

  • Method for histone enzymolysis by using outer membrane protease T and mass spectrum analysis

    CN109884163A